WO2019187218A1 - Novel protein, novel gene, transformant, method for producing transformant, and method for screening novel fluorescent protein - Google Patents

Novel protein, novel gene, transformant, method for producing transformant, and method for screening novel fluorescent protein Download PDF

Info

Publication number
WO2019187218A1
WO2019187218A1 PCT/JP2018/034338 JP2018034338W WO2019187218A1 WO 2019187218 A1 WO2019187218 A1 WO 2019187218A1 JP 2018034338 W JP2018034338 W JP 2018034338W WO 2019187218 A1 WO2019187218 A1 WO 2019187218A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
amino acid
base
novel
polynucleotide
Prior art date
Application number
PCT/JP2018/034338
Other languages
French (fr)
Japanese (ja)
Inventor
晃尚 清水
行大 白鳥
Original Assignee
Necソリューションイノベータ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Necソリューションイノベータ株式会社 filed Critical Necソリューションイノベータ株式会社
Priority to JP2020508958A priority Critical patent/JP6933409B2/en
Publication of WO2019187218A1 publication Critical patent/WO2019187218A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material

Definitions

  • the present invention relates to a novel protein, a novel gene, a transformant, a method for producing the transformant, and a method for screening a novel fluorescent protein.
  • Fluorescent proteins such as GFP (Green Fluorescent Protein) and YFP (Yellow Fluorescent Protein) are generally used (Non-Patent Document 1).
  • the fluorescent protein is used for various purposes such as research.
  • fluorescent proteins suitable for various applications do not necessarily exist. For this reason, a new fluorescent protein is required.
  • the novel protein of the present invention is the following protein (F1) or (F2).
  • F1 In the amino acid sequence of SEQ ID NO: 1, A protein comprising an amino acid sequence in which the 170th amino acid is an amino acid other than N (F2)
  • the amino acid sequence comprising the 170th amino acid consists of an amino acid sequence of 80% or more of the amino acid sequence of (F1), and Protein with drought resistance
  • the transformant of the present invention includes the novel gene of the present invention.
  • the novel fluorescent protein screening method of the present invention corresponds to the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 from the protein consisting of the amino acid sequence of SEQ ID NO: 1 or a candidate protein in which a mutation has been introduced into the novel protein of the present invention.
  • the method includes a selection step of selecting a protein having an amino acid other than N and having drying resistance.
  • a novel fluorescent protein can be provided.
  • FIG. 1 is a graph showing the fluorescence intensity of each protein in Example 2.
  • the novel protein of the present invention is the following protein (F1) or (F2).
  • F1 In the amino acid sequence of SEQ ID NO: 1, A protein comprising an amino acid sequence in which the 170th amino acid is an amino acid other than N (F2)
  • the amino acid sequence comprising the 170th amino acid consists of an amino acid sequence of 80% or more of the amino acid sequence of (F1), and Protein with drought resistance
  • the present inventors have found that the 170th amino acid in the protein having the amino acid sequence of SEQ ID NO: 1 is related to the drying resistance of the protein. For this reason, according to the novel protein of the present invention, by setting the 170th amino acid to any amino acid other than N (asparagine), the drying resistance of the protein can be adjusted. For example, the protein is strong even under dry conditions. A fluorescent protein can be obtained. The above estimation does not limit the present invention.
  • novel protein is also referred to as a novel fluorescent protein.
  • novel fluorescent protein is a protein newly prepared by the present inventors.
  • the novel fluorescent protein may include, for example, one type of protein or two or more types of proteins (hereinafter the same).
  • the amino acid sequence of SEQ ID NO: 1 is as follows. In the following amino acid sequence, the amino acid (N) surrounded by a square is the 170th amino acid (asparagine).
  • the protein having the amino acid sequence of SEQ ID NO: 1 is also referred to as CpYGFP, for example.
  • the 170th amino acid in SEQ ID NO: 1 is an amino acid other than N.
  • Amino acids other than N are A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y, preferably D or E.
  • Examples of the protein (F1) include proteins consisting of the amino acid sequences of SEQ ID NOs: 2 and 6.
  • the (F1) is also referred to as the YGFP N170D amino acid sequence and the YGFP N170E amino acid sequence, respectively.
  • amino acid sequences of SEQ ID NOs: 2 and 6 in (F1) are as follows.
  • the amino acid sequences of SEQ ID NOs: 2 and 6 correspond to the case where the 170th amino acid surrounded by a square in the amino acid sequence of SEQ ID NO: 1 is D and E, respectively.
  • the protein of (F2) is, for example, an amino acid sequence in which the 170th amino acid of (F1) is conserved and has 80% or more identity to the amino acid sequence of (F1), and has drought resistance. It can also be said to have a protein.
  • the “identity” may be, for example, a range in which the (F2) has the drying resistance.
  • “identity” is, for example, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more.
  • the “identity” can be calculated from default parameters using analysis software such as BLAST and FASTA (hereinafter the same).
  • the novel protein of the present invention may be the following protein (F3).
  • F3 A protein having a drought tolerance comprising an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and / or added in the amino acid sequence other than the 170th amino acid of (F1)
  • the 170th amino acid of (F1) is conserved, and in the amino acid sequence of (F1), one or several amino acids are deleted, substituted, inserted and / or added. It can also be referred to as a protein comprising a sequence and having drought resistance.
  • the “identity” may be, for example, a range in which the (F3) has the drying resistance.
  • “1 or several” means, for example, 1 to 43, 1 to 33, 1 to 22, 1 to 11, 1 to 9, 1 to 7, ⁇ 5, 1-3, 1 or 2.
  • the numerical range of numbers discloses, for example, all positive integers belonging to the range. That is, for example, the description “1 to 5” means all disclosures of “1, 2, 3, 4, 5” (hereinafter the same).
  • the novel fluorescent protein of the present invention has drought resistance. Having dry resistance means, for example, that a protein has fluorescence activity even when dried. Drying is, for example, a state in which the hydration water of the protein is relatively reduced as compared with the case where the protein is present in an aqueous solvent.
  • the method for measuring the drying resistance is not particularly limited.
  • the fluorescence intensity is measured before and after drying, and the fluorescence intensity before drying is compared with the fluorescence intensity after drying.
  • the drying resistance of the fluorescent protein can be confirmed.
  • the method for measuring the dry resistance may be performed, for example, according to the measurement method of Example 3 described later.
  • the excitation wavelength of the YGFP N170D is, for example, 400 to 410 nm, and the fluorescence wavelength is, for example, 503 to 513 nm.
  • the excitation wavelength of YGFP N170E is, for example, 401 to 411 nm, and the fluorescence wavelength is, for example, 500 to 510 nm.
  • the measurement method of the excitation wavelength, the excitation maximum wavelength, the fluorescence wavelength, and the fluorescence maximum wavelength is not particularly limited, and can be performed based on, for example, JIS K0120.
  • the measurement method of the excitation wavelength and the fluorescence wavelength may be performed, for example, according to the measurement method of Example 2 described later.
  • the novel fluorescent protein only needs to have drying resistance and fluorescent activity, and may further have other activities, for example.
  • the novel gene of the present invention is characterized by comprising at least one of the following polynucleotides (f1) and (f2).
  • (f1) a polynucleotide in which the 508th base, the 509th base, and the 510th base are mutated to a codon encoding an amino acid other than N in the base sequence of SEQ ID NO: 3
  • (f1) A polynucleotide encoding a protein comprising a nucleotide sequence having an identity of 80% or more and containing 508th base, 509th base, and 510th base, and having drought resistance
  • novel gene is a gene encoding the novel fluorescent protein of the present invention, it is hereinafter also referred to as a novel fluorescent protein gene.
  • novel fluorescent protein gene may contain, for example, one kind of polynucleotide or two or more kinds of polynucleotides (hereinafter the same).
  • the base sequence of SEQ ID NO: 3 in the above (f1) is as follows. In the following base sequence, the base (A) enclosed by a square is the 508th base. The underlined base (G) is the 381st base.
  • the protein encoded by the base sequence of SEQ ID NO: 3 is also referred to as CpYGFP, for example.
  • the polynucleotide consisting of the base sequence of SEQ ID NO: 3 is also referred to as CpYGFP polynucleotide.
  • the 508th base, the 509th base, and the 510th base are codons encoding amino acids other than N.
  • Codons encoding amino acids other than N are A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y.
  • Codon encoding preferably codon encoding D or E.
  • the 508th base is substituted with G, for example.
  • polynucleotide (f1) examples include polynucleotides consisting of the nucleotide sequences of SEQ ID NOs: 4 and 7.
  • (f1) is a polynucleotide comprising the nucleotide sequences of SEQ ID NOs: 4 and 7, the (f1) is also referred to as YGFP N170D 'and YGFP N170E polynucleotide.
  • the YGFP N170D ′ and YGFP N170E polynucleotides are polynucleotides encoding the amino acid sequence of YGFP N170D and the amino acid sequence of YGFP N170E, respectively.
  • the base sequences of SEQ ID NOs: 4 and 7 are as follows.
  • the base sequences of SEQ ID NOs: 4 and 7 are the same as those in the base sequence of SEQ ID NO: 3, when the 508th base surrounded by a square is replaced with G, and the 508th base surrounded by a square, This corresponds to the case where the 509th base and the 510th position are substituted with G, A, and G.
  • the underlined base (G) is the 381st base.
  • the polynucleotide (f2) when the 508th base is substituted with G, the polynucleotide (f2) preferably has the 508th base of (f1) conserved.
  • the polynucleotide of (f2) comprises the base sequence having the identity of 80% or more to the base sequence of (f1) in which the 508th base of (f1) is conserved.
  • the base 509, the 509th base, and the 510th base are preferably conserved.
  • the polynucleotide (f2) for example, the 508th base, the 509th base, and the 510th position of the (f1) are conserved, and 80% or more of the base sequence of the (f1) A polynucleotide encoding a protein having a drought tolerance.
  • polynucleotide (f2) examples include a polynucleotide having the base sequence of SEQ ID NO: 5.
  • (f2) is a base sequence consisting of SEQ ID NO: 5
  • the (f2) is also referred to as a YGFP N170D polynucleotide.
  • the YGFP N170D polynucleotide is a polynucleotide encoding the amino acid sequence of YGFP N170D.
  • the base sequence of SEQ ID NO: 5 is as follows.
  • the base sequence of SEQ ID NO: 5 corresponds to the case where the 508th base surrounded by a square and the 381 base underlined in the base sequence of SEQ ID NO: 3 are replaced with G and A, respectively. To do.
  • the novel gene of the present invention may be the following polynucleotides (f3) to (f7).
  • F3 In the base sequence other than the 508th base, the 509th base, and the 510th base, one or several bases are deleted, substituted, inserted and / or Alternatively, a polynucleotide comprising an added base sequence and encoding a protein having drought resistance (f4) From a base sequence complementary to a polynucleotide that hybridizes under stringent conditions to the polynucleotide of (f1) In the complementary sequence, a polynucleotide (f5) encoding a protein having a drought resistance in which bases corresponding to the 508th base, the 509th base, and the 510th base of (f1) are conserved In the amino acid sequence of SEQ ID NO: 1, the 170th amino acid is an amino acid other than N
  • the 508th base, the 509th base, and the 510th base of the (f1) are conserved.
  • one or several bases are stored. It can also be referred to as a polynucleotide that encodes a protein having a base sequence with deletion, substitution, insertion and / or addition, and having drought resistance.
  • “1 or several” may be, for example, within a range in which the protein encoded by the polynucleotide of (f3) has drought tolerance.
  • the “one or several” in (f3) is, for example, 1 to 132, 1 to 99, 1 to 66, 1 to 33, 1 to 26, 1 to 20, 1 to 13, 1-7, 1, 2, 3, or 4.
  • the polynucleotide of (f3) is the above (f1) It is preferable that the 508th base, the 509th base, and the 510th base are conserved.
  • the 508th base, the 509th base, and the 510th base of the (f1) are conserved, and one or several in the base sequence of the (f1)
  • the “one or several”, for example, the above description can be used.
  • the “hybridizing polynucleotide” is, for example, a polynucleotide that is completely or partially complementary to the polynucleotide of (f1).
  • the hybridization can be detected by, for example, various hybridization assays.
  • the hybridization assay is not particularly limited, for example, Zanburuku (Sambrook) et al., Eds., "Molecular Cloning: A Laboratory Manual 2nd Edition (Molecular Cloning:. A Laboratory Manual 2 nd Ed) ,” [Cold Spring Harbor Laboratory Press (1989)] and the like can also be employed.
  • the “stringent conditions” may be, for example, any of low stringent conditions, medium stringent conditions, and high stringent conditions.
  • Low stringent conditions are, for example, conditions of 5 ⁇ SSC, 5 ⁇ Denhardt's solution, 0.5% SDS, 50% formamide, and 32 ° C.
  • Medium stringent conditions are, for example, 5 ⁇ SSC, 5 ⁇ Denhardt's solution, 0.5% SDS, 50% formamide, 42 ° C.
  • “High stringent conditions” are, for example, conditions of 5 ⁇ SSC, 5 ⁇ Denhardt's solution, 0.5% SDS, 50% formamide, 50 ° C.
  • the degree of stringency can be set by those skilled in the art by appropriately selecting conditions such as temperature, salt concentration, probe concentration and length, ionic strength, time, and the like.
  • “Stringent conditions” are, for example, Zanburuku previously described (Sambrook) et al., Eds., "Molecular Cloning: A Laboratory Manual 2nd Edition (Molecular Cloning:. A Laboratory Manual 2 nd Ed) ,” [Cold Spring Harbor Laboratory Press ( 1989)]] and the like.
  • the polynucleotide (f5) may be any protein as long as the protein encoded by the polynucleotide (f5) has a drought resistance.
  • the base sequence of the polynucleotide of (f5) can be designed, for example, by replacing with the corresponding codon based on the amino acid sequence of SEQ ID NO: 1 and the 170th amino acid.
  • the protein encoded by the polynucleotide (f5) can also be referred to as, for example, the protein (F1) in the novel protein of the present invention, and the description thereof can be used.
  • “one or several” relating to the amino acid sequence may be within a range in which the protein encoded by the polynucleotide of (f6) has a drought tolerance, for example.
  • the “one or several” in (f6) is, for example, 1 to 43, 1 to 33, 1 to 22, 1 to 11, 1 to 9, 1 to 7, 1 to 5, One to three, one or two.
  • the protein encoded by the polynucleotide (f6) can also be referred to as the protein (F3) in the novel protein of the present invention, and the description thereof can be used.
  • the “identity” regarding the amino acid sequence may be, for example, within a range in which the protein encoded by the polynucleotide of (f7) has drought tolerance.
  • the identity of (f7) is, for example, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more.
  • the protein encoded by the polynucleotide (f7) can also be referred to as the protein (F2) in the novel protein of the present invention, and the description thereof can be used.
  • the various polynucleotides can be produced by, for example, a known genetic engineering technique or a synthetic technique.
  • the expression vector of the present invention is characterized by including the novel gene of the present invention.
  • the novel protein of the present invention can be easily produced by introducing the expression vector into the host.
  • the description of the novel gene of the present invention can be used for the expression vector of the present invention.
  • the expression vector only needs to contain the polynucleotide functionally so that, for example, the novel protein encoded by the polynucleotide that is the novel gene of the present invention can be expressed. Not limited.
  • the expression vector can be prepared, for example, by inserting the polynucleotide into a backbone vector (hereinafter also referred to as “basic vector”).
  • the type of the vector is not particularly limited, and can be appropriately determined according to the type of the host. Examples of the vector include viral vectors and non-viral vectors.
  • the vector is preferably a binary vector, for example. When transforming a plant, the vector is preferably a T-DNA type binary vector.
  • the vectors include, for example, pBI121 vector, pPZP202 vector, pBINPLUS vector, pBIN19 vector, pBIG2113N, pBIG2113SF, pRI101 DNA vector (manufactured by TaKaRa), pRI201 DNA vector ( TaKaRa), pRI909 DNA vector (TaKaRa), pRI910 DNA vector (TaKaRa), and the like.
  • a microorganism such as E.
  • the vectors include, for example, pETDuet-1 vector (Novagen), pQE-80L vector (QIAGEN), pBluescript II SK vector, pET101 / D-TOPO vector (manufactured by Invitrogen). ), PGEX-6P-1 vector (Amersham Biosciences), pcDNA3.2 / V5-GW / D-TOPO vector (Invitrogen), pEGFP vector, pcDNA3.1-hygro (-) vector (Invitrogen) Etc.
  • pETDuet-1 vector Novagen
  • pQE-80L vector QIAGEN
  • pBluescript II SK vector pET101 / D-TOPO vector
  • PGEX-6P-1 vector Amersham Biosciences
  • pcDNA3.2 / V5-GW / D-TOPO vector Invitrogen
  • pEGFP vector pcDNA3.1-hygro (-) vector (Invitrogen) Etc.
  • the expression vector preferably has a regulatory sequence that regulates, for example, the expression of the polynucleotide and the expression of the novel protein of the present invention encoded by the polynucleotide.
  • the regulatory sequence include a promoter, terminator, enhancer, polyadenylation signal sequence, origin of replication sequence (ori) and the like.
  • the arrangement of the regulatory sequences is not particularly limited.
  • the regulatory sequence may be arranged based on a known method as long as it is functionally regulated, for example, the expression of the polynucleotide and the expression of the novel protein encoded by the polynucleotide. .
  • the regulatory sequence for example, a sequence provided in advance in the basic vector may be used, the regulatory sequence may be further inserted into the basic vector, and the regulatory sequence provided in the basic vector It may be replaced with the regulatory sequence.
  • the expression vector may further include a selection marker coding sequence, for example.
  • a selection marker include drug resistance markers, fluorescent protein markers, enzyme markers, cell surface receptor markers, and the like.
  • the method for producing the novel protein of the present invention is not particularly limited, and for example, it may be produced by a genetic engineering technique or may be produced by a known synthesis method. In the former case, the production method of the present invention includes an expression step of expressing the novel gene of the present invention. Thereby, the manufacturing method of the novel protein of this invention can manufacture the said novel fluorescent protein of this invention easily, for example.
  • the expression of the polynucleotide which is the novel gene of the present invention may be performed using, for example, the expression vector of the present invention.
  • the method for expressing the polynucleotide is not particularly limited, and a known method can be adopted.
  • a cell-free protein synthesis system or a host may be used.
  • the polynucleotide is preferably expressed in a cell-free protein synthesis system.
  • an expression vector may be used for the expression of the polynucleotide.
  • the cell-free protein synthesis system can be performed by a known method using, for example, a cell extract, a buffer containing various components, and an expression vector into which the target polynucleotide has been introduced. Reagent kits can be used.
  • the host in which the polynucleotide is introduced it is preferable to use the host in which the polynucleotide is introduced and to express the polynucleotide in the host by culturing the host.
  • a transformant that synthesizes the novel protein of the present invention can be produced by introducing the polynucleotide into a host, and the novel protein of the present invention can be synthesized by culturing the transformant. .
  • Examples of the host include non-human hosts such as microorganisms, plants, animals, insects or cultured cells thereof, isolated human cells or cultured cells thereof, and preferably plants.
  • the plant When the host is a plant, the plant may be a plant body or a part thereof, for example.
  • Examples of the plant part include organs, tissues, cells, and vegetative propagation bodies.
  • Examples of the organ include petals, corolla, flowers, leaves, seeds, fruits, stems, roots and the like.
  • the tissue is, for example, a part of the organ.
  • Examples of the cells include cells collected from the plant or tissue thereof, cultured cells of the cells, protoplasts, and callus.
  • the origin of the plant is not particularly limited, and for example, Brassicaceae, Eggplant, Gramineae, Legumes, Rosaceae, Pteridomyceae, Asteraceae, Gentianaceae, Ganodermaceae, Oenaceae, Primula, Cactiaceae, Orchidaceae Department and so on.
  • Brassicaceae include the Arabidopsis genus such as Arabidopsis thaliana .
  • the family Solanaceae for example, tobacco (Nicotiana tabacum) Nicotiana such as petunia (Petunia ⁇ hybrida) petunias genus such as (Petunia), Nierembergia (Nierembergia hippoamanica) Amamodoki genus such as, Calibrachoa (Calibrachoa hybrid Cultivar) such Examples include the genus Calibrachoa.
  • Examples of the Gramineae include a genus of maize such as corn ( Zea mays ) and a genus of rice such as rice ( Oryza sativa ).
  • the legumes include soybean genus such as soybean ( Glycine max ).
  • the rose family for example, the genus Rosa such as roses (Rosa), and the like.
  • Examples of the Nadesico family include Nadesico genus such as carnation ( Dianthus caryophyllus ).
  • the Compositae family for example, chrysanthemum, such as cultivation chrysanthemum (Chrysantemum morifolium), Gerbera (Gerbera cvs.) Gerbera (Oosenbon'yari) genus, etc., and the like.
  • the Gentianaceae includes, for example, Eustoma genus such as Eustoma grandiflorum .
  • Examples of the genus Pleurotus include Torenia ( Torenia tenteri ) Torenia.
  • Examples of the family Oleaceae include Verbena genus such as Verbena ( Garden verbena ).
  • the Primulaceae for example, Cyclamen spp such as cyclamen (Cyclamen persicum) and the like.
  • the cactus family includes, for example, Austrokilondropuntia, Astrophytum, Echinocactus, Echinocereus, Echinopsis, Epiphylam, Opuntia, Crab Cactus, Kamaecereus, Kirindropuntia, Gymnocalycium Cactus cactus genus, Serenicerus genus, Teflocactus genus, Neobox baumia genus, Neoraimondia genus, Nopalea genus, Ferrocactus genus, Mamiglia genus, Melocatus genus, Lipsalis genus, Roseocactus genus, Lofophora genus
  • Phalaenopsis Phalaenopsis cvs.
  • Phalaenopsis Phalaenopsis
  • Cymbidium Cymbidium cvs.
  • Cymbidium Chunlan
  • Nobile system Dendrobium Dendrobium nobile hybrids
  • Denfare system Dendrobium D. phalaenopsis hybrids
  • Oncidium genus such as Oncidium cvs.
  • Cattleya genus such as Cattleya cvs .
  • the microorganism include eukaryotes and prokaryotes.
  • the prokaryotes for example, E.
  • Escherichia coli Escherichia genus such as Pseudomonas putida (Pseudomonas putida) Pseudomonas such as bacteria and the like.
  • the eukaryote include yeasts such as Saccharomyces cerevisiae .
  • the animal cells include COS cells and CHO cells, and examples of the insect cells include Sf9 and Sf21.
  • a method for introducing the polynucleotide into the host that is, a method for transformation of the host is not particularly limited, and for example, a method using the expression vector may be used, or the expression vector is not used. It may be a known method introduced into. In the latter case, the introduction method can be appropriately set depending on, for example, the type of the host.
  • the introduction method examples include heat shock method, lithium acetate method, introduction method using gene gun such as particle gun, calcium phosphate method, polyethylene glycol method, lipofection method using liposome, electroporation method, ultrasonic nucleic acid introduction method, DEAE -A dextran method, a direct injection method using a micro glass tube, a hydrodynamic method, a cationic liposome method, a method using an introduction aid, a method using Agrobacterium, and the like.
  • the liposome include lipofectamine and cationic liposome
  • the introduction aid include atelocollagen, nanoparticles, and polymers.
  • the introduction method is preferably an Agrobacterium-mediated method.
  • the polynucleotide which is the novel gene of the present invention may be introduced into the host by the expression vector of the present invention, for example.
  • the method for culturing the host is not particularly limited, and can be appropriately set according to the type of the host.
  • the medium used for culturing the host is not particularly limited, and can be appropriately determined according to the type of the host.
  • the form of the medium used for culturing the host is not particularly limited, and a conventionally known medium such as a solid medium, a liquid medium, or an agar medium can be used as appropriate.
  • the components contained in the medium are not particularly limited.
  • the medium may include a commercially available medium, for example.
  • the commercial medium of the plant is not particularly limited, and examples thereof include Murashige-Skoog (MS) medium.
  • MS Murashige-Skoog
  • the commercially available medium for the plant cell is not particularly limited, and examples thereof include hyponex medium, MS medium, Gamborg B5 (B5) medium, White medium and the like.
  • the commercially available medium for the microorganism is not particularly limited, and examples thereof include LB medium, super broth medium, M9 medium and the like.
  • examples thereof include LB medium, super broth medium, M9 medium and the like.
  • one type of the medium may be used alone, or two or more types may be used in combination.
  • the pH of the medium is not particularly limited, and is, for example, in the range of pH 6 to 8, or in the range of pH 6.5 to 7.5.
  • the method for culturing the host is not particularly limited, and can be appropriately determined according to, for example, the type of the host.
  • examples of the culture method include a method of cultivating the plant in soil and water.
  • examples of the culture method include callus culture, root culture, ovule culture, embryo culture, and the like.
  • the culture temperature at the time of culturing the host is not particularly limited and can be appropriately determined according to, for example, the type of the host.
  • examples of the culture temperature include a plant-growing temperature and an optimum growth temperature.
  • the culture temperature can be, for example, in the range of 15 to 40 ° C., in the range of 30 to 37 ° C.
  • examples of the culture temperature include a plant cell growth temperature and a growth optimum temperature.
  • the culture temperature can be, for example, in the range of 15 to 40 ° C., in the range of 30 to 37 ° C.
  • the host may be cultured under an aerobic condition or an anaerobic condition, for example.
  • the aerobic condition or the anaerobic condition is not particularly limited, and can be set using a conventionally known method.
  • the transformant of the present invention includes the novel gene of the present invention.
  • the transformant of the present invention is characterized by including the novel gene of the present invention, and other configurations and conditions are not particularly limited. Since the transformant of the present invention contains the novel gene of the present invention, it has, for example, drought tolerance.
  • the transformant of the present invention for example, the description of the novel protein of the present invention can be used.
  • the transformant is not particularly limited, and examples thereof include animals and plants, but plants are preferred.
  • examples of the transformant include cancer cells such as human colon cancer cells.
  • the origin of the plant and the plant is not particularly limited, and for example, the above description can be used.
  • the plant may be a plant body or a part thereof, for example.
  • the plant part include organs, tissues, cells, and vegetative propagation bodies.
  • the organ include petals, corolla, flowers, leaves, seeds, fruits, stems, roots and the like.
  • the tissue is, for example, a part of the organ.
  • Examples of the cells include cells collected from the plant or tissue thereof, cultured cells of the cells, protoplasts, and callus.
  • the transformant of the present invention when the transformant is a plant, the transformant of the present invention can be further propagated, for example. At this time, the transformant of the present invention can be used as the propagation material.
  • the propagation material is not particularly limited, and may be the whole or a part of the transformant, for example.
  • examples of the propagation material include seeds, fruits, shoots, stems such as tubers, roots such as tuberous roots, strains, protoplasts, and callus.
  • the propagation method of the transformant of the present invention is not particularly limited, and a known method can be adopted.
  • the breeding method may be, for example, sexual reproduction or asexual reproduction, preferably asexual reproduction.
  • the reproduction by asexual reproduction includes, for example, vegetative propagation and is also called vegetative reproduction.
  • the method of vegetative propagation is not particularly limited, and in the case of the plant body or a part thereof, for example, bud propagation, propagation by cuttings, subdividing from an organ to a plant individual, growth by callus, and the like can be mentioned.
  • the organ for example, the leaves, stems, roots and the like as described above can be used.
  • the vegetative propagation material of the present invention preferably has the same properties as the transformant of the present invention.
  • the vegetative propagation material of the present invention is not particularly limited as in the case of the transformant, and examples thereof include a plant or a part thereof.
  • progeny such as growths grown from the seeds can be obtained. It is preferable that the progeny of the present invention obtains the same properties as the transformant of the present invention.
  • the progeny of the present invention may be, for example, a plant or a part thereof, for example, like the transformant.
  • the transformant of the present invention may be further processed, for example.
  • the kind of the transformant to be processed is not particularly limited, and examples thereof include flowers, leaves, branches and the like.
  • the processed product of the transformant is not particularly limited, and examples thereof include potpourri, dried flowers, dried flowers, preserved flowers, and resin-sealed products obtained by drying flowers, leaves, branches and the like.
  • the processed product of the present invention may be, for example, a processed product of a vegetative propagation body, organ, tissue or cell of the transformant.
  • the method for producing a transformant of the present invention includes an introduction step of introducing the novel gene of the present invention into a host.
  • the method for producing a transformant of the present invention is characterized by including an introduction step for introducing the novel gene of the present invention into a host, and other steps and conditions are not particularly limited. According to the method for producing a transformant of the present invention, for example, the transformant of the present invention can be easily produced.
  • the method for producing a transformant of the present invention may further include an expression step for expressing the novel gene in the host.
  • the method for introducing the novel gene of the present invention into the host is not particularly limited.
  • the description of the method for introducing the polynucleotide into the host in the method for producing the novel protein of the present invention is used. it can.
  • the host is preferably a plant.
  • the expression step is, for example, a step of expressing the novel protein of the present invention from the novel gene of the present invention in a host.
  • the host is preferably, for example, a transformant introduced with the novel gene of the present invention or the expression vector, and the novel protein of the present invention is expressed in the host by culturing the transformant. It is preferable to express.
  • the method for producing a transformant of the present invention may further include a breeding step for breeding the transformant obtained by the introducing step.
  • a breeding method in the breeding process for example, the above description can be used.
  • the method for producing a transformant of the present invention may include a seeding step for seeding from the propagated transformant, and may further include a growth step for growing a growth body from the seed obtained in the seeding step. .
  • the novel fluorescent protein screening method of the present invention is the amino acid of SEQ ID NO: 1 from the candidate protein in which mutation is introduced into the novel protein of the present invention. It includes a selection step in which the 170th amino acid in the sequence is an amino acid other than N and a protein having drought resistance is included, and the other steps and conditions are not particularly limited.
  • a protein having fluorescence activity can be easily screened.
  • the description of the novel protein, novel gene, expression vector, production method and the like of the present invention can be used.
  • the candidate protein is a protein obtained by introducing a mutation into the novel protein of the present invention.
  • the type of mutation introduced into the novel protein is not particularly limited, and examples thereof include amino acid deletion, substitution, insertion and / or addition.
  • the candidate protein is, for example, a protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of the novel protein, or the amino acid of the novel protein Examples of the protein include an amino acid sequence having 80% or more identity to the sequence.
  • “1 or several” means, for example, 1 to 43, 1 to 33, 1 to 22, 1 to 11, 1 to 9, 1 to 7, 1 to Five, one to three, one or two.
  • identity is, for example, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more.
  • the candidate protein may be produced by a known protein synthesis method based on the amino acid sequence of the candidate protein, or may be produced by a genetic engineering technique.
  • the screening method of the present invention includes, for example, a nucleotide sequence encoding the novel protein, that is, a mutation step of introducing a mutation into the novel gene of the present invention to produce a mutant polynucleotide, An expression step of expressing the candidate protein.
  • the mutation to be introduced into the novel gene is not particularly limited, and is, for example, base deletion, substitution, insertion and / or addition.
  • the method for introducing a mutation into the novel gene is not particularly limited, and can be carried out, for example, by a known method for introducing a mutation into a polynucleotide. Specific examples include random fragmentation of the polynucleotide of the novel gene of the present invention. Examples include a method of reconstructing a gene by recombination using PCR (so-called DNA shuffling method).
  • the method for expressing the mutant polynucleotide is not particularly limited.
  • the description of the method for producing a novel protein of the present invention described above can be used, and a cell-free protein synthesis system may be used.
  • a host may be used.
  • the host is preferably, for example, a prokaryote, particularly Escherichia coli .
  • the screening method of the present invention may include, for example, a step of purifying the candidate protein obtained in the expression step.
  • the purification method is not particularly limited, and examples thereof include salting out and various column chromatography.
  • the solvent used in the various purification steps is not particularly limited, and for example, a buffer solution can be used.
  • the candidate protein obtained in the expression step may be used as it is in the selection step described later, or a partially purified candidate protein that is partially purified may be used. A single purified candidate protein may be used.
  • the selection step is a step of selecting, from the candidate proteins, a protein having an amino acid corresponding to the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 other than N and having drought resistance.
  • the amino acid corresponding to the 170th amino acid of the selected candidate protein is an amino acid other than N.
  • Amino acids other than N are A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y, preferably D or E.
  • the selected candidate protein has the 170th amino acid substituted with, for example, D or E, and has drying resistance.
  • the method for identifying the amino acid sequence of the candidate protein is not particularly limited, and can be performed by, for example, a known amino acid identification method.
  • the amino acid sequence of the candidate protein may be identified, for example, by replacing the codon of the base sequence of the mutant polynucleotide with the corresponding amino acid sequence.
  • the method for confirming the drying resistance of the candidate protein is not particularly limited, and a known method for confirming drying resistance can be used. For example, it can be confirmed by the same method as the method for measuring the drying resistance.
  • the selection step it is preferable to select a protein having an amino acid sequence having 80% or more identity to the amino acid sequence of SEQ ID NO: 1 and having drought tolerance.
  • the “identity” may be, for example, a range in which the selected candidate protein has the drought tolerance.
  • the “identity” is, for example, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more.
  • Example 1 It was confirmed that a novel fluorescent protein can be screened by the screening method of the present invention.
  • a mutated polynucleotide was prepared, and the mutated polynucleotide was linked to a vector to construct a mutated polynucleotide expression vector. Specifically, it was performed as follows. First, a CpYGFP polynucleotide (SEQ ID NO: 3) was amplified by PCR (Polymerase Chain Reaction) using the following primer set to obtain a mutant polynucleotide into which mutations were randomly inserted. A PCR reaction solution was prepared according to the instructions using a kit of GeneMorph II Random Mutagenesis Kit (200550, manufactured by Agilent Technologies).
  • Primer set Primer sequence 1 (SEQ ID NO: 8) 5'-ATGCTTCCGGCTCGTATGTTG-3 '
  • Primer sequence 2 (SEQ ID NO: 9) 5'-GTACGGCCGACTAGTAGGCC-3 '
  • the mutant polynucleotide was cleaved with restriction enzymes HindIII and EcoRI and ligated to a pEGFP vector (manufactured by Clonetec) cleaved with the restriction enzyme.
  • a pEGFP vector a vector in which a sequence (CpYGFP vector insertion sequence (SEQ ID NO: 10)) having a His tag sequence added to the 5 'end of a CpYGFP polynucleotide (SEQ ID NO: 3) was used in the EGFP portion.
  • the base sequence of the vector insertion sequence (SEQ ID NO: 10) is as follows.
  • the base sequence enclosed in parentheses is the base sequence corresponding to the CpYGFP polynucleotide, and the underlined base sequence outside the parentheses is the His tag sequence.
  • the vector into which the mutant polynucleotide was inserted was used as a mutant polynucleotide expression vector. In this way, a large number of mutant polynucleotide expression vectors were obtained.
  • the obtained suspension was subjected to ultrasonic treatment using an ultrasonic homogenizer (QSONICA, manufactured by Wakken Pharmaceutical Co., Ltd.) under the conditions of Amp 30% and 1 minute. And the suspension after the said process was centrifuged for 10 minutes on the conditions of 1300 rpm and 4 degreeC, and the obtained supernatant was collect
  • 0.2 ml (50% slurry) of TALON (registered trademark) Metal Affinity Resin (Z5502N, manufactured by TAKARA) was added and reacted at room temperature for 1 hour.
  • the reaction solution was washed with a PBS solution, and then 0.5 ml of a PBS solution containing 300 mM imidazole was added to elute the protein. Then, using Amicon Ultra-0.5 (UFC5010, manufactured by Merck Millipore), the reaction solution was subjected to buffer exchange and replaced with a PBS solution.
  • the purified sample obtained from the transformant was designated as YGFP N170D protein and used in the following experiments.
  • the protein concentration in each purified sample was determined by diluting each sample with a 10% SDS solution and then developing the color using a Pierce BCA Protein Assay Kit (# 23225, manufactured by Pierce), and using a microplate reader (Infinite (registered) (Trademark) M1000Pro, manufactured by TECAN) was used to determine the absorbance at 562 nm.
  • a purified sample containing YGFP N170E protein was prepared from the microbial cells having the novel gene (SEQ ID NO: 7) of the present invention.
  • the YGFP N170D protein and the YGFP N170E protein are each diluted based on the protein concentration obtained in (1) so that the protein concentration in the sample is 2 ⁇ mol / L. did.
  • fluorescence intensity FI
  • 70 ⁇ L of the diluted sample fluorescence intensity (FI) was measured under the following measurement conditions using the microplate reader.
  • BK15 SEQ ID NO: 11
  • the amino acid sequence of SEQ ID NO: 11 is as follows. In the following amino acid sequence, the amino acid (N) surrounded by a square is the 170th amino acid (asparagine).
  • the excitation wavelength (Ex) is 405 nm and the fluorescence wavelength (Em) is 508 nm.
  • the excitation wavelength (Ex) is 406 nm and the fluorescence wavelength (Em) is 505 nm.
  • Table 1 shows the results and the results for the positive control (BK15) when the excitation wavelength (Ex) is 398 nm and the fluorescence wavelength (Em) is 512 nm. As shown in Table 1, YGFP N170D and YGFP N170E showed higher fluorescence activity than BK15. From this result, it was found that the novel fluorescent protein of the present invention has fluorescent activity.
  • Dry resistance was measured using YGFP N170D and YGFP N170E of Example 2. The measurement of drying resistance was performed as follows.
  • the YGFP N170D protein and YGFP N170E protein are diluted based on the protein concentration obtained in Example 2 (1) so that the protein concentration in the sample is 5 and 0.5 ⁇ g / mL, respectively. did.
  • the measurement of drought resistance was performed using a microfiltration apparatus (Bio-Dot (registered trademark), manufactured by Biorad). Three biodot SF filter papers (1620161, manufactured by Biorad) were arranged as filter paper, and a nitrocellulose membrane (162-0147, manufactured by Biorad) was used as a membrane. 500 ⁇ L of each diluted sample (equivalent to 2.5 and 0.25 ⁇ g of the protein, respectively) was dispensed into the wells of the device.
  • FIG. 1 shows the results of photographing the fluorescence of YGFP N170D in Day 1 and Day 7 immediately after blotting.
  • the results of adsorbing 2.5, 0.25 and 0 ⁇ g of the protein in order from the left are shown.
  • the results of YGFP N170D, YGFP N170E and BK15 are shown.
  • YGFP N170D, YGFP N170E, and BK15 bands were detected in the lane where 2.5 ⁇ g of protein was adsorbed.
  • YGFP N170D, YGFP N170E and BK15 bands were slightly detected.
  • Day 1 the bands of YGFP N170D and YGFP N170E were detected in the lane where 2.5 ⁇ g of protein was adsorbed.
  • the BK15 band was slightly detected.
  • Day 7 bands of YGFP N170D and YGFP N170E were detected in the lane where 2.5 ⁇ g of protein was adsorbed.
  • the BK15 band was slightly detected.
  • YGFP N170E had fluorescent activity even after 1 day and 7 days had passed since the start of drying. From the above, it was found that the novel fluorescent protein of the present invention has drought resistance compared to BK15.
  • a novel fluorescent protein can be provided.
  • the present invention can be said to be an extremely useful technique in fields such as the life science field, the medical field, and the agricultural field.
  • (Appendix 1) A novel protein characterized by being a protein of the following (F1) or (F2).
  • F1 In the amino acid sequence of SEQ ID NO: 1, A protein comprising an amino acid sequence in which the 170th amino acid is an amino acid other than N (F2)
  • the amino acid sequence comprising the 170th amino acid consists of an amino acid sequence of 80% or more of the amino acid sequence of (F1), and Protein with drought resistance
  • Appendix 2 The novel protein according to appendix 1, wherein the protein of (F1) is a protein comprising at least one amino acid sequence of SEQ ID NOs: 2 and 6.
  • (Appendix 3) A novel gene comprising at least one of the following polynucleotides (f1) and (f2): (F1) a polynucleotide in which the 508th base, the 509th base, and the 510th base are mutated to a codon encoding an amino acid other than N in the base sequence of SEQ ID NO: 3 (f1) A polynucleotide encoding a protein having a nucleotide sequence of 80% or more identity including the 508th base, the 509th base, and the 510th base, and having a drought resistance (Notes) 4) In the base sequence of SEQ ID NO: 3, The novel gene according to appendix 3, wherein the 508th base, the 509th base, and the 510th base are codons encoding at least one of D and E.
  • (Appendix 5) The novel gene according to appendix 3 or 4, wherein the 381st base is replaced with A.
  • (Appendix 6) The novel gene according to any one of appendices 3 to 5, wherein the polynucleotide of (f1) is a polynucleotide comprising at least one base sequence of SEQ ID NOs: 4 and 7.
  • (Appendix 7) The novel gene according to any one of appendices 3 to 6, wherein the polynucleotide (f2) is a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 5.
  • (Appendix 8) An expression vector comprising the novel gene according to any one of appendices 3 to 7.
  • (Appendix 9) A transformant comprising the novel gene according to any one of appendices 3 to 7.
  • Appendix 10) The transformant according to appendix 9, wherein the transformant is a plant.
  • (Appendix 11) A method for producing a transformant, comprising an introduction step of introducing the novel gene according to any one of appendices 3 to 7 into a host.
  • (Appendix 12) The method for producing a transformant according to appendix 11, further comprising an expression step of expressing the novel gene in the host.
  • (Appendix 13) The method for producing a transformant according to appendix 11 or 12, wherein the host is a plant.
  • An amino acid corresponding to the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 is an amino acid other than N, from a protein comprising the amino acid sequence of SEQ ID NO: 1 or a candidate protein in which a mutation has been introduced into the novel protein of Appendix 1 or 2;
  • the amino acid corresponding to the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 is D or E; The screening method according to appendix 14, wherein a protein having drought resistance is selected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Provided is a novel fluorescent protein. The novel protein according to the present invention is characterized by being protein (F1) or (F2). (F1) A protein which comprises an amino acid sequence represented by SEQ ID NO: 1 wherein the 170th amino acid is an amino acid other than N. (F2) A protein which comprises an amino acid sequence having 80% or higher identity including the 170th amino acid with the amino acid sequence of (F1) and which has desiccation tolerance.

Description

新規タンパク質、新規遺伝子、形質転換体、形質転換体の製造方法、および新規蛍光タンパク質のスクリーニング方法Novel protein, novel gene, transformant, method for producing transformant, and method for screening novel fluorescent protein
 本発明は、新規タンパク質、新規遺伝子、形質転換体、形質転換体の製造方法、および新規蛍光タンパク質のスクリーニング方法に関する。 The present invention relates to a novel protein, a novel gene, a transformant, a method for producing the transformant, and a method for screening a novel fluorescent protein.
 蛍光タンパク質として、GFP(Green Fluorescent Protein)やYFP(Yellow Fluorescent Protein)等が、一般的に用いられている(非特許文献1)。前記蛍光タンパク質は、研究等の様々な用途に使用されている。しかしながら、各種用途に適した蛍光タンパク質が、必ずしも存在するわけではない。このため、新たな蛍光タンパク質が求められている。 Fluorescent proteins such as GFP (Green Fluorescent Protein) and YFP (Yellow Fluorescent Protein) are generally used (Non-Patent Document 1). The fluorescent protein is used for various purposes such as research. However, fluorescent proteins suitable for various applications do not necessarily exist. For this reason, a new fluorescent protein is required.
 そこで、本発明は、新たな蛍光タンパク質を提供することを目的とする。 Therefore, an object of the present invention is to provide a new fluorescent protein.
 本発明の新規タンパク質は、下記(F1)または(F2)のタンパク質であることを特徴とする。
(F1) 配列番号1のアミノ酸配列において、
170番目のアミノ酸がN以外のアミノ酸であるアミノ酸配列からなるタンパク質
(F2) 前記(F1)のアミノ酸配列に対して、170番目のアミノ酸を含む同一性が80%以上のアミノ酸配列からなり、且つ、乾燥耐性を有するタンパク質
The novel protein of the present invention is the following protein (F1) or (F2).
(F1) In the amino acid sequence of SEQ ID NO: 1,
A protein comprising an amino acid sequence in which the 170th amino acid is an amino acid other than N (F2) The amino acid sequence comprising the 170th amino acid consists of an amino acid sequence of 80% or more of the amino acid sequence of (F1), and Protein with drought resistance
 本発明の新規遺伝子は、下記(f1)または(f2)のポリヌクレオチドであることを特徴とする。
(f1) 配列番号3の塩基配列において、508番目の塩基、509番目の塩基、および510番目の塩基が、N以外のアミノ酸をコードするコドンに変異しているポリヌクレオチド
(f2) 前記(f1)のポリヌクレオチドに対して、508番目の塩基、509番目の塩基、および510番目の塩基を含む同一性が80%以上の塩基配列からなり、且つ、乾燥耐性を有するタンパク質をコードするポリヌクレオチド
The novel gene of the present invention is characterized by the following polynucleotide (f1) or (f2).
(F1) a polynucleotide in which the 508th base, the 509th base, and the 510th base are mutated to a codon encoding an amino acid other than N in the base sequence of SEQ ID NO: 3 (f1) A polynucleotide encoding a protein comprising a nucleotide sequence having an identity of 80% or more and containing 508th base, 509th base, and 510th base, and having drought resistance
 本発明の形質転換体は、前記本発明の新規遺伝子を含むことを特徴とする。 The transformant of the present invention includes the novel gene of the present invention.
 本発明の形質転換体の製造方法は、宿主に、前記本発明の新規遺伝子を導入する導入工程を含むことを特徴とする。 The method for producing a transformant of the present invention is characterized by including an introducing step of introducing the novel gene of the present invention into a host.
 本発明の新規蛍光タンパク質のスクリーニング方法は、配列番号1のアミノ酸配列からなるタンパク質または前記本発明の新規タンパク質に変異を導入した候補タンパク質から、配列番号1のアミノ酸配列における170番目のアミノ酸に対応するアミノ酸がN以外のアミノ酸であり、且つ乾燥耐性を有するタンパク質を選抜する選抜工程を含むことを特徴とする。 The novel fluorescent protein screening method of the present invention corresponds to the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 from the protein consisting of the amino acid sequence of SEQ ID NO: 1 or a candidate protein in which a mutation has been introduced into the novel protein of the present invention. The method includes a selection step of selecting a protein having an amino acid other than N and having drying resistance.
 本発明によれば、新規な蛍光タンパク質を提供できる。 According to the present invention, a novel fluorescent protein can be provided.
図1は、実施例2における各タンパクの蛍光強度を示すグラフである。FIG. 1 is a graph showing the fluorescence intensity of each protein in Example 2.
<新規タンパク質>
 本発明の新規タンパク質は、前述のように、下記(F1)または(F2)のタンパク質であることを特徴とする。
(F1) 配列番号1のアミノ酸配列において、
170番目のアミノ酸がN以外のアミノ酸であるアミノ酸配列からなるタンパク質
(F2) 前記(F1)のアミノ酸配列に対して、170番目のアミノ酸を含む同一性が80%以上のアミノ酸配列からなり、且つ、乾燥耐性を有するタンパク質
<New protein>
As described above, the novel protein of the present invention is the following protein (F1) or (F2).
(F1) In the amino acid sequence of SEQ ID NO: 1,
A protein comprising an amino acid sequence in which the 170th amino acid is an amino acid other than N (F2) The amino acid sequence comprising the 170th amino acid consists of an amino acid sequence of 80% or more of the amino acid sequence of (F1), and Protein with drought resistance
 本発明者らは鋭意研究の結果、前記配列番号1のアミノ酸配列を有するタンパク質において、170番目のアミノ酸が、前記タンパク質の乾燥耐性と関連性を有することを見出した。このため、本発明の新規タンパク質によれば、170番目のアミノ酸をN(アスパラギン)以外の任意のアミノ酸とすることにより、前記タンパク質の乾燥耐性を調整でき、例えば、乾燥した条件下においても、強い蛍光を発するタンパク質を得られる。なお、上記推定は、本発明を何ら制限しない。 As a result of intensive studies, the present inventors have found that the 170th amino acid in the protein having the amino acid sequence of SEQ ID NO: 1 is related to the drying resistance of the protein. For this reason, according to the novel protein of the present invention, by setting the 170th amino acid to any amino acid other than N (asparagine), the drying resistance of the protein can be adjusted. For example, the protein is strong even under dry conditions. A fluorescent protein can be obtained. The above estimation does not limit the present invention.
 以下、前記新規タンパク質は、新規蛍光タンパク質ともいう。前記新規蛍光タンパク質は、本発明者らが新たに作製したタンパク質である。本発明において、前記新規蛍光タンパク質は、例えば、1種類のタンパク質を含んでもよいし、2種類以上のタンパク質を含んでもよい(以下、同様)。 Hereinafter, the novel protein is also referred to as a novel fluorescent protein. The novel fluorescent protein is a protein newly prepared by the present inventors. In the present invention, the novel fluorescent protein may include, for example, one type of protein or two or more types of proteins (hereinafter the same).
 配列番号1のアミノ酸配列は、以下の通りである。以下のアミノ酸配列において、四角で囲んだアミノ酸(N)は、170番目のアミノ酸(アスパラギン)である。前記配列番号1のアミノ酸配列を有するタンパク質を、例えば、CpYGFPともいう。 The amino acid sequence of SEQ ID NO: 1 is as follows. In the following amino acid sequence, the amino acid (N) surrounded by a square is the 170th amino acid (asparagine). The protein having the amino acid sequence of SEQ ID NO: 1 is also referred to as CpYGFP, for example.
Figure JPOXMLDOC01-appb-I000001
Figure JPOXMLDOC01-appb-I000001
 前記(F1)のタンパク質は、配列番号1における170番目のアミノ酸がN以外のアミノ酸である。N以外のアミノ酸は、A、C、D、E、F、G、H、I、K、L、M、P、Q、R、S、T、V、W、またはYであり、好ましくは、DまたはEである。 In the protein (F1), the 170th amino acid in SEQ ID NO: 1 is an amino acid other than N. Amino acids other than N are A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y, preferably D or E.
 前記(F1)のタンパク質は、例えば、配列番号2および6のアミノ酸配列からなるタンパク質があげられる。前記(F1)が配列番号2および6のアミノ酸配列からなるタンパク質である場合、前記(F1)は、それぞれ、YGFP N170Dのアミノ酸配列、およびYGFP N170Eのアミノ酸配列ともいう。 Examples of the protein (F1) include proteins consisting of the amino acid sequences of SEQ ID NOs: 2 and 6. When the (F1) is a protein consisting of the amino acid sequences of SEQ ID NOs: 2 and 6, the (F1) is also referred to as the YGFP N170D amino acid sequence and the YGFP N170E amino acid sequence, respectively.
 前記(F1)における配列番号2および6のアミノ酸配列は、以下の通りである。前記配列番号2および6のアミノ酸配列は、前記配列番号1のアミノ酸配列において、四角で囲んだ170番目のアミノ酸が、それぞれ、DおよびEの場合に対応する。 The amino acid sequences of SEQ ID NOs: 2 and 6 in (F1) are as follows. The amino acid sequences of SEQ ID NOs: 2 and 6 correspond to the case where the 170th amino acid surrounded by a square in the amino acid sequence of SEQ ID NO: 1 is D and E, respectively.
Figure JPOXMLDOC01-appb-I000002
Figure JPOXMLDOC01-appb-I000002
Figure JPOXMLDOC01-appb-I000003
Figure JPOXMLDOC01-appb-I000003
 前記(F2)のタンパク質は、例えば、前記(F1)の170番目のアミノ酸が保存され、前記(F1)のアミノ酸配列に対して、80%以上の同一性を有するアミノ酸配列からなり、乾燥耐性を有するタンパク質ということもできる。前記(F2)において、「同一性」は、例えば、前記(F2)が、前記乾燥耐性を有する範囲であればよい。前記(F2)のアミノ酸配列において、「同一性」は、例えば、80%以上、85%以上、90%以上、95%以上、96%以上、97%以上、98%以上、99%以上である。前記「同一性」は、例えば、BLAST、FASTA等の解析ソフトウェアを用いて、デフォルトのパラメータにより算出できる(以下、同様)。 The protein of (F2) is, for example, an amino acid sequence in which the 170th amino acid of (F1) is conserved and has 80% or more identity to the amino acid sequence of (F1), and has drought resistance. It can also be said to have a protein. In the (F2), the “identity” may be, for example, a range in which the (F2) has the drying resistance. In the amino acid sequence of (F2), “identity” is, for example, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more. . The “identity” can be calculated from default parameters using analysis software such as BLAST and FASTA (hereinafter the same).
 本発明の新規タンパク質は、下記(F3)のタンパク質でもよい。
(F3) 前記(F1)の170番目のアミノ酸以外のアミノ酸配列において、1もしくは数個のアミノ酸が欠失、置換、挿入および/または付加されたアミノ酸配列からなり、乾燥耐性を有するタンパク質
The novel protein of the present invention may be the following protein (F3).
(F3) A protein having a drought tolerance comprising an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and / or added in the amino acid sequence other than the 170th amino acid of (F1)
 前記(F3)のタンパク質は、前記(F1)の170番目のアミノ酸が保存され、前記(F1)のアミノ酸配列において、1もしくは数個のアミノ酸が欠失、置換、挿入および/または付加されたアミノ酸配列からなり、乾燥耐性を有するタンパク質ということもできる。前記(F3)において、「同一性」は、例えば、前記(F3)が、前記乾燥耐性を有する範囲であればよい。前記(F3)のアミノ酸配列において、「1もしくは数個」は、例えば、1~43個、1~33個、1~22個、1~11個、1~9個、1~7個、1~5個、1~3個、1または2個である。本発明において、個数の数値範囲は、例えば、その範囲に属する正の整数を全て開示するものである。つまり、例えば、「1~5個」との記載は、「1、2、3、4、5個」の全ての開示を意味する(以下、同様)。 In the protein (F3), the 170th amino acid of (F1) is conserved, and in the amino acid sequence of (F1), one or several amino acids are deleted, substituted, inserted and / or added. It can also be referred to as a protein comprising a sequence and having drought resistance. In the (F3), the “identity” may be, for example, a range in which the (F3) has the drying resistance. In the amino acid sequence of (F3), “1 or several” means, for example, 1 to 43, 1 to 33, 1 to 22, 1 to 11, 1 to 9, 1 to 7, ~ 5, 1-3, 1 or 2. In the present invention, the numerical range of numbers discloses, for example, all positive integers belonging to the range. That is, for example, the description “1 to 5” means all disclosures of “1, 2, 3, 4, 5” (hereinafter the same).
 本発明の新規蛍光タンパク質は、乾燥耐性を有する。乾燥耐性を有するとは、例えば、タンパク質が、乾燥しても、蛍光活性を有することである。乾燥とは、例えば、タンパク質が水性溶媒中に存在する場合と比較して、前記タンパク質の水和水が相対的に減少した状態である。 The novel fluorescent protein of the present invention has drought resistance. Having dry resistance means, for example, that a protein has fluorescence activity even when dried. Drying is, for example, a state in which the hydration water of the protein is relatively reduced as compared with the case where the protein is present in an aqueous solvent.
 前記乾燥耐性の測定方法は、特に制限されず、例えば、対象蛍光タンパク質について、乾燥前後において、蛍光強度を測定し、乾燥前の蛍光強度と乾燥後の蛍光強度とを比較することにより、前記対象蛍光タンパク質の乾燥耐性を確認できる。前記乾燥耐性の測定方法は、例えば、後述する実施例3の測定方法に準じて行ってもよい。 The method for measuring the drying resistance is not particularly limited. For example, for the target fluorescent protein, the fluorescence intensity is measured before and after drying, and the fluorescence intensity before drying is compared with the fluorescence intensity after drying. The drying resistance of the fluorescent protein can be confirmed. The method for measuring the dry resistance may be performed, for example, according to the measurement method of Example 3 described later.
 本発明の新規蛍光タンパク質は、例えば、以下のような化学的特性を有する。以下の励起波長、励起極大波長、蛍光波長および蛍光極大波長は、例えば、350~650nmの波長の範囲における化学的特性である。
励起波長:350~650nm
励起極大波長:386~514nm
蛍光波長:350~650nm
蛍光極大波長:506~524nm
The novel fluorescent protein of the present invention has the following chemical characteristics, for example. The following excitation wavelength, excitation maximum wavelength, fluorescence wavelength and fluorescence maximum wavelength are chemical characteristics in the wavelength range of 350 to 650 nm, for example.
Excitation wavelength: 350 to 650 nm
Excitation maximum wavelength: 386 to 514 nm
Fluorescence wavelength: 350-650nm
Fluorescence maximum wavelength: 506 to 524 nm
 本発明の新規蛍光タンパク質が前記YGFP N170Dである場合、前記YGFP N170Dの励起波長は、例えば、400~410nmであり、蛍光波長は、例えば、503~513nmである。 When the novel fluorescent protein of the present invention is the YGFP N170D, the excitation wavelength of the YGFP N170D is, for example, 400 to 410 nm, and the fluorescence wavelength is, for example, 503 to 513 nm.
 本発明の新規蛍光タンパク質が前記YGFP N170Eである場合、前記YGFP N170Eの励起波長は、例えば、401~411nmであり、蛍光波長は、例えば、500~510nmである。 When the novel fluorescent protein of the present invention is YGFP N170E, the excitation wavelength of YGFP N170E is, for example, 401 to 411 nm, and the fluorescence wavelength is, for example, 500 to 510 nm.
 前記励起波長、前記励起極大波長、前記蛍光波長、および前記蛍光極大波長の測定方法は、特に制限されず、例えば、JIS K0120に基づいて行うことができる。前記励起波長および前記蛍光波長の測定方法は、例えば、後述する実施例2の測定方法に準じて行ってもよい。 The measurement method of the excitation wavelength, the excitation maximum wavelength, the fluorescence wavelength, and the fluorescence maximum wavelength is not particularly limited, and can be performed based on, for example, JIS K0120. The measurement method of the excitation wavelength and the fluorescence wavelength may be performed, for example, according to the measurement method of Example 2 described later.
 前記新規蛍光タンパク質は、乾燥耐性および蛍光活性を有していればよく、例えば、さらに、その他の活性を有してもよい。 The novel fluorescent protein only needs to have drying resistance and fluorescent activity, and may further have other activities, for example.
<新規遺伝子>
 本発明の新規遺伝子は、前述のように、下記(f1)および(f2)の少なくとも一方のポリヌクレオチドからなることを特徴とする。
(f1) 配列番号3の塩基配列において、508番目の塩基、509番目の塩基、および510番目の塩基が、N以外のアミノ酸をコードするコドンに変異しているポリヌクレオチド
(f2) 前記(f1)のポリヌクレオチドに対して、508番目の塩基、509番目の塩基、および510番目の塩基を含む同一性が80%以上の塩基配列からなり、且つ、乾燥耐性を有するタンパク質をコードするポリヌクレオチド
<New gene>
As described above, the novel gene of the present invention is characterized by comprising at least one of the following polynucleotides (f1) and (f2).
(F1) a polynucleotide in which the 508th base, the 509th base, and the 510th base are mutated to a codon encoding an amino acid other than N in the base sequence of SEQ ID NO: 3 (f1) A polynucleotide encoding a protein comprising a nucleotide sequence having an identity of 80% or more and containing 508th base, 509th base, and 510th base, and having drought resistance
 前記新規遺伝子は、前記本発明の新規蛍光タンパク質をコードする遺伝子であることから、以下、新規蛍光タンパク質遺伝子ともいう。前記新規蛍光タンパク質遺伝子は、例えば、1種類のポリヌクレオチドを含んでもよいし、2種類以上のポリヌクレオチドを含んでもよい(以下、同様)。 Since the novel gene is a gene encoding the novel fluorescent protein of the present invention, it is hereinafter also referred to as a novel fluorescent protein gene. The novel fluorescent protein gene may contain, for example, one kind of polynucleotide or two or more kinds of polynucleotides (hereinafter the same).
 前記(f1)における配列番号3の塩基配列は、以下の通りである。以下の塩基配列において、四角で囲んだ塩基(A)は、508番目の塩基である。下線を引いた塩基(G)は、381番目の塩基である。前記配列番号3の塩基配列がコードするタンパク質を、例えば、CpYGFPともいう。また、配列番号3の塩基配列からなるポリヌクレオチドを、CpYGFPのポリヌクレオチドともいう。 The base sequence of SEQ ID NO: 3 in the above (f1) is as follows. In the following base sequence, the base (A) enclosed by a square is the 508th base. The underlined base (G) is the 381st base. The protein encoded by the base sequence of SEQ ID NO: 3 is also referred to as CpYGFP, for example. The polynucleotide consisting of the base sequence of SEQ ID NO: 3 is also referred to as CpYGFP polynucleotide.
Figure JPOXMLDOC01-appb-I000004
Figure JPOXMLDOC01-appb-I000004
 前記(f1)のポリヌクレオチドは、508番目の塩基、509番目の塩基、および510番目の塩基が、N以外のアミノ酸をコードするコドンである。前記N以外のアミノ酸をコードするコドンは、A、C、D、E、F、G、H、I、K、L、M、P、Q、R、S、T、V、W、またはYをコードするコドンであり、好ましくは、DまたはEをコードするコドンである。 In the polynucleotide (f1), the 508th base, the 509th base, and the 510th base are codons encoding amino acids other than N. Codons encoding amino acids other than N are A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y. Codon encoding, preferably codon encoding D or E.
 本発明の新規蛍光タンパク質遺伝子において、508番目の塩基は、例えば、Gに置換されている。 In the novel fluorescent protein gene of the present invention, the 508th base is substituted with G, for example.
 前記(f1)のポリヌクレオチドは、例えば、配列番号4および7の塩基配列からなるポリヌクレオチドがあげられる。前記(f1)が配列番号4および7の塩基配列からなるポリヌクレオチドである場合、前記(f1)は、YGFP N170D’およびYGFP N170Eのポリヌクレオチドともいう。YGFP N170D’およびYGFP N170Eのポリヌクレオチドは、それぞれ、YGFP N170Dのアミノ酸配列、およびYGFP N170Eのアミノ酸配列をコードするポリヌクレオチドである。 Examples of the polynucleotide (f1) include polynucleotides consisting of the nucleotide sequences of SEQ ID NOs: 4 and 7. When (f1) is a polynucleotide comprising the nucleotide sequences of SEQ ID NOs: 4 and 7, the (f1) is also referred to as YGFP N170D 'and YGFP N170E polynucleotide. The YGFP N170D ′ and YGFP N170E polynucleotides are polynucleotides encoding the amino acid sequence of YGFP N170D and the amino acid sequence of YGFP N170E, respectively.
 配列番号4および7の塩基配列は、以下の通りである。前記配列番号4および7の塩基配列は、前記配列番号3の塩基配列において、それぞれ、四角で囲んだ508番目の塩基が、Gに置換されている場合、ならびに四角で囲んだ508番目の塩基、509番目の塩基、および510番目が、G、A、およびGに置換されている場合に対応する。下線を引いた塩基(G)は、381番目の塩基である。 The base sequences of SEQ ID NOs: 4 and 7 are as follows. The base sequences of SEQ ID NOs: 4 and 7 are the same as those in the base sequence of SEQ ID NO: 3, when the 508th base surrounded by a square is replaced with G, and the 508th base surrounded by a square, This corresponds to the case where the 509th base and the 510th position are substituted with G, A, and G. The underlined base (G) is the 381st base.
Figure JPOXMLDOC01-appb-I000005
Figure JPOXMLDOC01-appb-I000005
Figure JPOXMLDOC01-appb-I000006
Figure JPOXMLDOC01-appb-I000006
 前記(f2)のポリヌクレオチドは、例えば、前記(f1)の508番目の塩基、509番目の塩基、および510番目の塩基が保存され、前記(f1)の塩基配列に対して、80%以上の同一性を有する塩基配列からなり、乾燥耐性を有するタンパク質をコードするポリヌクレオチドということもできる。前記(f2)において、「同一性」は、例えば、前記(f2)のポリヌクレオチドによってコードされるタンパク質が、乾燥耐性を有する範囲であればよい。前記(f2)の同一性は、例えば、80%以上、85%以上、90%以上、95%以上、96%以上、97%以上、98%以上、99%以上である。前記(f1)において、508番目の塩基が、Gに置換されている場合、前記(f2)のポリヌクレオチドは、前記(f1)の508番目の塩基が保存されていることが好ましい。この場合、前記(f2)のポリヌクレオチドは、例えば、前記(f1)の508番目の塩基が保存され、前記(f1)の塩基配列に対して、80%以上の同一性を有する塩基配列からなり、乾燥耐性を有するタンパク質をコードするポリヌクレオチドである。前記(f1)において、508番目の塩基、509番目の塩基、および510番目が、G、A、およびGに置換されている場合、前記(f2)のポリヌクレオチドは、前記(f1)の508番目の塩基、509番目の塩基、および510番目の塩基が保存されていることが好ましい。この場合、前記(f2)のポリヌクレオチドは、例えば、前記(f1)の508番目の塩基、509番目の塩基、および510番目が保存され、前記(f1)の塩基配列に対して、80%以上の同一性を有する塩基配列からなり、乾燥耐性を有するタンパク質をコードするポリヌクレオチドである。 In the polynucleotide (f2), for example, the 508th base, the 509th base, and the 510th base of (f1) are conserved, and 80% or more of the base sequence of (f1) is stored. It can also be called a polynucleotide encoding a protein having a nucleotide sequence having identity and having drought resistance. In the above (f2), the “identity” may be, for example, a range in which the protein encoded by the polynucleotide of (f2) has drought tolerance. The identity of (f2) is, for example, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more. In the case of (f1), when the 508th base is substituted with G, the polynucleotide (f2) preferably has the 508th base of (f1) conserved. In this case, for example, the polynucleotide of (f2) comprises the base sequence having the identity of 80% or more to the base sequence of (f1) in which the 508th base of (f1) is conserved. A polynucleotide encoding a protein having drought tolerance. In the above (f1), when the 508th base, the 509th base, and the 510th are substituted with G, A, and G, the polynucleotide of (f2) is the 508th of (f1). The base 509, the 509th base, and the 510th base are preferably conserved. In this case, in the polynucleotide (f2), for example, the 508th base, the 509th base, and the 510th position of the (f1) are conserved, and 80% or more of the base sequence of the (f1) A polynucleotide encoding a protein having a drought tolerance.
 本発明の新規蛍光タンパク質遺伝子において、381番目の塩基は、例えば、Aに置換されている。 In the novel fluorescent protein gene of the present invention, the 381st base is substituted with A, for example.
 前記(f2)のポリヌクレオチドは、例えば、配列番号5の塩基配列からなるポリヌクレオチドがあげられる。前記(f2)が配列番号5からなる塩基配列である場合、前記(f2)は、YGFP N170Dのポリヌクレオチドともいう。YGFP N170Dのポリヌクレオチドは、YGFP N170Dのアミノ酸配列をコードするポリヌクレオチドである。 Examples of the polynucleotide (f2) include a polynucleotide having the base sequence of SEQ ID NO: 5. When (f2) is a base sequence consisting of SEQ ID NO: 5, the (f2) is also referred to as a YGFP N170D polynucleotide. The YGFP N170D polynucleotide is a polynucleotide encoding the amino acid sequence of YGFP N170D.
 配列番号5の塩基配列は、以下の通りである。前記配列番号5の塩基配列は、前記配列番号3の塩基配列において、四角で囲んだ508番目の塩基および下線を引いた381番目の塩基が、それぞれ、GおよびAに置換されている場合に対応する。 The base sequence of SEQ ID NO: 5 is as follows. The base sequence of SEQ ID NO: 5 corresponds to the case where the 508th base surrounded by a square and the 381 base underlined in the base sequence of SEQ ID NO: 3 are replaced with G and A, respectively. To do.
Figure JPOXMLDOC01-appb-I000007
Figure JPOXMLDOC01-appb-I000007
 本発明の新規遺伝子は、下記(f3)~(f7)のポリヌクレオチドでもよい。
(f3) 前記(f1)のポリヌクレオチドに対して、508番目の塩基、509番目の塩基、および510番目の塩基以外の塩基配列において、1もしくは数個の塩基が欠失、置換、挿入および/または付加された塩基配列からなり、乾燥耐性を有するタンパク質をコードするポリヌクレオチド
(f4) 前記(f1)のポリヌクレオチドに対してストリンジェントな条件下でハイブリダイズするポリヌクレオチドに相補的な塩基配列からなり、前記相補的な配列において、前記(f1)の508番目の塩基、509番目の塩基、および510番目の塩基に対応する塩基が保存され、乾燥耐性を有するタンパク質をコードするポリヌクレオチド
(f5) 配列番号1のアミノ酸配列において、170番目のアミノ酸が、N以外のアミノ酸であるタンパク質をコードするポリヌクレオチド
(f6) 前記(f5)の170番目のアミノ酸以外のアミノ酸配列において、1もしくは数個のアミノ酸が欠失、置換、挿入および/または付加されたアミノ酸配列からなり、乾燥耐性を有するタンパク質をコードするポリヌクレオチド
(f7) 前記(f5)の170番目のアミノ酸以外のアミノ酸配列に対して、80%以上の同一性を有するアミノ酸配列からなり、乾燥耐性を有するタンパク質をコードするポリヌクレオチド
The novel gene of the present invention may be the following polynucleotides (f3) to (f7).
(F3) In the base sequence other than the 508th base, the 509th base, and the 510th base, one or several bases are deleted, substituted, inserted and / or Alternatively, a polynucleotide comprising an added base sequence and encoding a protein having drought resistance (f4) From a base sequence complementary to a polynucleotide that hybridizes under stringent conditions to the polynucleotide of (f1) In the complementary sequence, a polynucleotide (f5) encoding a protein having a drought resistance in which bases corresponding to the 508th base, the 509th base, and the 510th base of (f1) are conserved In the amino acid sequence of SEQ ID NO: 1, the 170th amino acid is an amino acid other than N A polynucleotide encoding a protein (f6) consisting of an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted and / or added in the amino acid sequence other than the 170th amino acid of (f5), and dried Polynucleotide encoding a protein having resistance (f7) An amino acid sequence having 80% or more identity to the amino acid sequence other than the 170th amino acid of (f5), and encoding a protein having drought resistance Polynucleotide
 前記(f3)のポリヌクレオチドは、例えば、前記(f1)の508番目の塩基、509番目の塩基、および510番目の塩基が保存され、前記(f1)のポリヌクレオチドにおいて、1もしくは数個の塩基が欠失、置換、挿入および/または付加された塩基配列からなり、乾燥耐性を有するタンパク質をコードするポリヌクレオチドということもできる。前記(f3)において、「1もしくは数個」は、例えば、前記(f3)のポリヌクレオチドによってコードされるタンパク質が、乾燥耐性を有する範囲であればよい。前記(f3)の「1もしくは数個」は、例えば、1~132個、1~99個、1~66個、1~33個、1~26個、1~20個、1~13個、1~7個、1個、2個、3個、または4個である。前記(f1)において、508番目の塩基、509番目の塩基、および510番目の塩基が、DまたはEをコードするコドンに置換されている場合、前記(f3)のポリヌクレオチドは、前記(f1)の508番目の塩基、509番目の塩基、および510番目の塩基が保存されていることが好ましい。この場合、前記(f3)のポリヌクレオチドは、例えば、前記(f1)の508番目の塩基、509番目の塩基、および510番目の塩基が保存され、前記(f1)の塩基配列において、1もしくは数個の塩基が欠失、置換、挿入および/または付加された塩基配列からなり、乾燥耐性を有するタンパク質をコードするポリヌクレオチドである。前記「1もしくは数個」は、例えば、前述の説明を援用できる。 In the polynucleotide (f3), for example, the 508th base, the 509th base, and the 510th base of the (f1) are conserved. In the polynucleotide (f1), one or several bases are stored. It can also be referred to as a polynucleotide that encodes a protein having a base sequence with deletion, substitution, insertion and / or addition, and having drought resistance. In the above (f3), “1 or several” may be, for example, within a range in which the protein encoded by the polynucleotide of (f3) has drought tolerance. The “one or several” in (f3) is, for example, 1 to 132, 1 to 99, 1 to 66, 1 to 33, 1 to 26, 1 to 20, 1 to 13, 1-7, 1, 2, 3, or 4. In the above (f1), when the 508th base, the 509th base, and the 510th base are substituted with a codon encoding D or E, the polynucleotide of (f3) is the above (f1) It is preferable that the 508th base, the 509th base, and the 510th base are conserved. In this case, in the polynucleotide (f3), for example, the 508th base, the 509th base, and the 510th base of the (f1) are conserved, and one or several in the base sequence of the (f1) A polynucleotide encoding a protein having a drought tolerance consisting of a base sequence in which one base is deleted, substituted, inserted and / or added. As the “one or several”, for example, the above description can be used.
 前記(f4)において、「ハイブリダイズするポリヌクレオチド」は、例えば、前記(f1)のポリヌクレオチドに対して、完全または部分的に相補的なポリヌクレオチドである。前記ハイブリダイズは、例えば、各種ハイブリダイゼーションアッセイにより検出できる。前記ハイブリダイゼーションアッセイは、特に制限されず、例えば、ザンブルーク(Sambrook)ら編「モレキュラー・クローニング:ア・ラボラトリーマニュアル第2版(Molecular Cloning: A Laboratory Manual 2nd Ed.)」〔Cold Spring Harbor Laboratory Press (1989)〕等に記載されている方法を採用することもできる。 In (f4), the “hybridizing polynucleotide” is, for example, a polynucleotide that is completely or partially complementary to the polynucleotide of (f1). The hybridization can be detected by, for example, various hybridization assays. The hybridization assay is not particularly limited, for example, Zanburuku (Sambrook) et al., Eds., "Molecular Cloning: A Laboratory Manual 2nd Edition (Molecular Cloning:. A Laboratory Manual 2 nd Ed) ," [Cold Spring Harbor Laboratory Press (1989)] and the like can also be employed.
 前記(f4)において、「ストリンジェントな条件」は、例えば、低ストリンジェントな条件、中ストリンジェントな条件、高ストリンジェントな条件のいずれでもよい。「低ストリンジェントな条件」は、例えば、5×SSC、5×デンハルト溶液、0.5%SDS、50%ホルムアミド、32℃の条件である。「中ストリンジェントな条件」は、例えば、5×SSC、5×デンハルト溶液、0.5%SDS、50%ホルムアミド、42℃の条件である。「高ストリンジェントな条件」は、例えば、5×SSC、5×デンハルト溶液、0.5%SDS、50%ホルムアミド、50℃の条件である。ストリンジェンシーの程度は、当業者であれば、例えば、温度、塩濃度、プローブの濃度および長さ、イオン強度、時間等の条件を適宜選択することで、設定可能である。「ストリンジェントな条件」は、例えば、前述したザンブルーク(Sambrook)ら編「モレキュラー・クローニング:ア・ラボラトリーマニュアル第2版(Molecular Cloning: A Laboratory Manual 2nd Ed.)」〔Cold Spring Harbor Laboratory Press (1989)〕等に記載の条件を採用することもできる。 In the above (f4), the “stringent conditions” may be, for example, any of low stringent conditions, medium stringent conditions, and high stringent conditions. “Low stringent conditions” are, for example, conditions of 5 × SSC, 5 × Denhardt's solution, 0.5% SDS, 50% formamide, and 32 ° C. “Medium stringent conditions” are, for example, 5 × SSC, 5 × Denhardt's solution, 0.5% SDS, 50% formamide, 42 ° C. “High stringent conditions” are, for example, conditions of 5 × SSC, 5 × Denhardt's solution, 0.5% SDS, 50% formamide, 50 ° C. The degree of stringency can be set by those skilled in the art by appropriately selecting conditions such as temperature, salt concentration, probe concentration and length, ionic strength, time, and the like. "Stringent conditions" are, for example, Zanburuku previously described (Sambrook) et al., Eds., "Molecular Cloning: A Laboratory Manual 2nd Edition (Molecular Cloning:. A Laboratory Manual 2 nd Ed) ," [Cold Spring Harbor Laboratory Press ( 1989)]] and the like.
 前記(f5)のポリヌクレオチドは、例えば、前記(f5)のポリヌクレオチドによってコードされるタンパク質が、乾燥耐性を有する塩基配列であればよい。前記(f5)のポリヌクレオチドの塩基配列は、例えば、前記配列番号1のアミノ酸配列および170番目のアミノ酸に基づいて、対応するコドンに置き換えることで設計可能である。前記(f5)のポリヌクレオチドによってコードされるタンパク質は、例えば、前記本発明の新規タンパク質における(F1)のタンパク質ということもでき、その説明を援用できる。 The polynucleotide (f5) may be any protein as long as the protein encoded by the polynucleotide (f5) has a drought resistance. The base sequence of the polynucleotide of (f5) can be designed, for example, by replacing with the corresponding codon based on the amino acid sequence of SEQ ID NO: 1 and the 170th amino acid. The protein encoded by the polynucleotide (f5) can also be referred to as, for example, the protein (F1) in the novel protein of the present invention, and the description thereof can be used.
前記(f6)において、アミノ酸配列に関する「1もしくは数個」は、例えば、前記(f6)のポリヌクレオチドによってコードされるタンパク質が、乾燥耐性を有する範囲であればよい。前記(f6)の「1もしくは数個」は、例えば、1~43個、1~33個、1~22個、1~11個、1~9個、1~7個、1~5個、1~3個、1または2個である。前記(f6)のポリヌクレオチドによってコードされるタンパク質は、前記本発明の新規タンパク質における前記(F3)のタンパク質ということもでき、その説明を援用できる。 In the above (f6), “one or several” relating to the amino acid sequence may be within a range in which the protein encoded by the polynucleotide of (f6) has a drought tolerance, for example. The “one or several” in (f6) is, for example, 1 to 43, 1 to 33, 1 to 22, 1 to 11, 1 to 9, 1 to 7, 1 to 5, One to three, one or two. The protein encoded by the polynucleotide (f6) can also be referred to as the protein (F3) in the novel protein of the present invention, and the description thereof can be used.
前記(f7)において、アミノ酸配列に関する「同一性」は、例えば、前記(f7)のポリヌクレオチドによってコードされるタンパク質が、乾燥耐性を有する範囲であればよい。前記(f7)の同一性は、例えば、80%以上、85%以上、90%以上、95%以上、96%以上、97%以上、98%以上、99%以上である。前記(f7)のポリヌクレオチドによってコードされるタンパク質は、前記本発明の新規タンパク質における前記(F2)のタンパク質ということもでき、その説明を援用できる。 In the above (f7), the “identity” regarding the amino acid sequence may be, for example, within a range in which the protein encoded by the polynucleotide of (f7) has drought tolerance. The identity of (f7) is, for example, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more. The protein encoded by the polynucleotide (f7) can also be referred to as the protein (F2) in the novel protein of the present invention, and the description thereof can be used.
 本発明において、前記各種ポリヌクレオチドは、例えば、公知の遺伝子工学的手法または合成手法によって製造できる。 In the present invention, the various polynucleotides can be produced by, for example, a known genetic engineering technique or a synthetic technique.
<新規タンパク質の発現ベクター>
 本発明の発現ベクターは、前述のように、前記本発明の新規遺伝子を含むことを特徴とする。本発明の発現ベクターによれば、例えば、前記発現ベクターを前記宿主に導入することで、前記本発明の新規タンパク質を容易に製造できる。本発明の発現ベクターは、例えば、前記本発明の新規遺伝子の説明等を援用できる。
<New protein expression vector>
As described above, the expression vector of the present invention is characterized by including the novel gene of the present invention. According to the expression vector of the present invention, for example, the novel protein of the present invention can be easily produced by introducing the expression vector into the host. For example, the description of the novel gene of the present invention can be used for the expression vector of the present invention.
 前記発現ベクターは、例えば、前記本発明の新規遺伝子である前記ポリヌクレオチドがコードする新規タンパク質を発現可能なように、機能的に、前記ポリヌクレオチドを含んでいればよく、その他の構成は、特に制限されない。 The expression vector only needs to contain the polynucleotide functionally so that, for example, the novel protein encoded by the polynucleotide that is the novel gene of the present invention can be expressed. Not limited.
 前記発現ベクターは、例えば、骨格となるベクター(以下、「基本ベクター」ともいう。)に、前記ポリヌクレオチドを挿入することで作製できる。前記ベクターの種類は、特に制限されず、例えば、前記宿主の種類に応じて、適宜決定できる。前記ベクターは、ウイルスベクターおよび非ウイルスベクターがあげられる。前記ベクターは、例えば、バイナリーベクターが好ましい。植物に形質転換を行う場合、前記ベクターは、T-DNA型バイナリーベクターが好ましい。アグロバクテリウムを使用する方法により、植物に形質転換を行う場合、前記ベクターは、例えば、pBI121ベクター、pPZP202ベクター、pBINPLUSベクター、pBIN19ベクター、pBIG2113N、pBIG2113SF、pRI101DNAベクター(TaKaRa社製)、pRI201DNAベクター(TaKaRa社製)、pRI909DNAベクター(TaKaRa社製)、pRI910DNAベクター(TaKaRa社製)等があげられる。大腸菌等の微生物に形質転換を行う場合、前記ベクターは、例えば、pETDuet-1ベクター(ノバジェン社)、pQE-80Lベクター(QIAGEN社)、pBluescript II SKベクター、pET101/D-TOPOベクター(Invitrogen社製)、pGEX-6P-1ベクター(Amersham Biosciences社製)、pcDNA3.2/V5-GW/D-TOPOベクター(Invitrogen社製)、pEGFPベクター、pcDNA3.1-hygro(-)ベクター(Invitrogen社製)等があげられる。 The expression vector can be prepared, for example, by inserting the polynucleotide into a backbone vector (hereinafter also referred to as “basic vector”). The type of the vector is not particularly limited, and can be appropriately determined according to the type of the host. Examples of the vector include viral vectors and non-viral vectors. The vector is preferably a binary vector, for example. When transforming a plant, the vector is preferably a T-DNA type binary vector. When a plant is transformed by a method using Agrobacterium, the vectors include, for example, pBI121 vector, pPZP202 vector, pBINPLUS vector, pBIN19 vector, pBIG2113N, pBIG2113SF, pRI101 DNA vector (manufactured by TaKaRa), pRI201 DNA vector ( TaKaRa), pRI909 DNA vector (TaKaRa), pRI910 DNA vector (TaKaRa), and the like. When a microorganism such as E. coli is transformed, the vectors include, for example, pETDuet-1 vector (Novagen), pQE-80L vector (QIAGEN), pBluescript II SK vector, pET101 / D-TOPO vector (manufactured by Invitrogen). ), PGEX-6P-1 vector (Amersham Biosciences), pcDNA3.2 / V5-GW / D-TOPO vector (Invitrogen), pEGFP vector, pcDNA3.1-hygro (-) vector (Invitrogen) Etc.
 前記発現ベクターは、例えば、前記ポリヌクレオチドの発現および前記ポリヌクレオチドがコードする前記本発明の新規タンパク質の発現を調節する、調節配列を有することが好ましい。前記調節配列は、例えば、プロモーター、ターミネーター、エンハンサー、ポリアデニル化シグナル配列、複製起点配列(ori)等があげられる。前記発現ベクターにおいて、前記調節配列の配置は特に制限されない。前記発現ベクターにおいて、前記調節配列は、例えば、前記ポリヌクレオチドの発現およびこれがコードする前記新規タンパク質の発現を、機能的に調節できるように配置されていればよく、公知の方法に基づいて配置できる。前記調節配列は、例えば、前記基本ベクターが予め備える配列を利用してもよいし、前記基本ベクターに、さらに、前記調節配列を挿入してもよいし、前記基本ベクターが備える調節配列を、他の調節配列に置き換えてもよい。 The expression vector preferably has a regulatory sequence that regulates, for example, the expression of the polynucleotide and the expression of the novel protein of the present invention encoded by the polynucleotide. Examples of the regulatory sequence include a promoter, terminator, enhancer, polyadenylation signal sequence, origin of replication sequence (ori) and the like. In the expression vector, the arrangement of the regulatory sequences is not particularly limited. In the expression vector, the regulatory sequence may be arranged based on a known method as long as it is functionally regulated, for example, the expression of the polynucleotide and the expression of the novel protein encoded by the polynucleotide. . As the regulatory sequence, for example, a sequence provided in advance in the basic vector may be used, the regulatory sequence may be further inserted into the basic vector, and the regulatory sequence provided in the basic vector It may be replaced with the regulatory sequence.
 前記発現ベクターは、例えば、さらに、選択マーカーのコード配列を有してもよい。前記選択マーカーは、例えば、薬剤耐性マーカー、蛍光タンパク質マーカー、酵素マーカー、細胞表面レセプターマーカー等があげられる。 The expression vector may further include a selection marker coding sequence, for example. Examples of the selection marker include drug resistance markers, fluorescent protein markers, enzyme markers, cell surface receptor markers, and the like.
<新規タンパク質の製造方法>
 本発明の新規タンパク質の製造方法は、特に制限されず、例えば、遺伝子工学的手法により製造してもよいし、公知の合成方法により製造してもよい。前者の場合、本発明の製造方法は、前記本発明の新規遺伝子を発現させる発現工程を含む。これにより、本発明の新規タンパク質の製造方法は、例えば、前記本発明の新規蛍光タンパク質を容易に製造できる。
<Method for producing novel protein>
The method for producing the novel protein of the present invention is not particularly limited, and for example, it may be produced by a genetic engineering technique or may be produced by a known synthesis method. In the former case, the production method of the present invention includes an expression step of expressing the novel gene of the present invention. Thereby, the manufacturing method of the novel protein of this invention can manufacture the said novel fluorescent protein of this invention easily, for example.
 前記本発明の新規遺伝子であるポリヌクレオチドの発現は、例えば、前記本発明の発現ベクターを使用して行ってもよい。 The expression of the polynucleotide which is the novel gene of the present invention may be performed using, for example, the expression vector of the present invention.
 前記ポリヌクレオチドを発現させる方法は、特に制限されず、公知の方法が採用でき、例えば、無細胞タンパク質合成系を使用してもよいし、宿主を使用してもよい。 The method for expressing the polynucleotide is not particularly limited, and a known method can be adopted. For example, a cell-free protein synthesis system or a host may be used.
 前者の場合、無細胞タンパク質合成系において前記ポリヌクレオチドを発現させることが好ましい。この場合、前記ポリヌクレオチドの発現には、発現ベクターを使用してもよい。前記無細胞タンパク質合成系は、例えば、細胞抽出液と、各種成分を含むバッファーと、目的のポリヌクレオチドが導入された発現ベクターとを用いて、公知の方法により行うことができ、例えば、市販の試薬キットが使用できる。 In the former case, the polynucleotide is preferably expressed in a cell-free protein synthesis system. In this case, an expression vector may be used for the expression of the polynucleotide. The cell-free protein synthesis system can be performed by a known method using, for example, a cell extract, a buffer containing various components, and an expression vector into which the target polynucleotide has been introduced. Reagent kits can be used.
 後者の場合、例えば、前記ポリヌクレオチドが導入された前記宿主を使用し、前記宿主の培養により、前記宿主において前記ポリヌクレオチドを発現させることが好ましい。このように、例えば、前記ポリヌクレオチドを宿主に導入することで、本発明の新規タンパク質を合成する形質転換体を製造でき、また、前記形質転換体の培養により、本発明の新規タンパク質を合成できる。 In the latter case, for example, it is preferable to use the host in which the polynucleotide is introduced and to express the polynucleotide in the host by culturing the host. Thus, for example, a transformant that synthesizes the novel protein of the present invention can be produced by introducing the polynucleotide into a host, and the novel protein of the present invention can be synthesized by culturing the transformant. .
 前記宿主は、例えば、微生物、植物、動物、昆虫またはこれらの培養細胞等の非ヒト宿主、単離したヒト細胞またはその培養細胞等があげられ、好ましくは、植物である。前記宿主が植物の場合、前記植物は、例えば、植物体またはその部分であってもよい。前記植物体の部分は、例えば、器官、組織、細胞または栄養繁殖体等があげられる。前記器官は、例えば、花弁、花冠、花、葉、種子、果実、茎、根等があげられる。前記組織は、例えば、前記器官の部分である。前記細胞は、例えば、前記植物体またはその組織から採取した細胞、前記細胞の培養細胞、プロトプラスト、カルス等があげられる。前記植物の由来は、特に制限されず、例えば、アブラナ科、ナス科、イネ科、マメ科、バラ科、ナデシコ科、キク科、リンドウ科、ゴマノハグサ科、クマツヅラ科、サクラソウ科、サボテン科、ラン科等があげられる。前記アブラナ科は、例えば、シロイヌナズナ(Arabidopsis thaliana)等のシロイヌナズナ属等があげられる。前記ナス科は、例えば、タバコ(Nicotiana tabacum)等のタバコ属、ペチュニア(Petunia×hybrida)等のツクバネアサガオ属(Petunia)、ニーレンベルギア(Nierembergia hippoamanica)等のアマモドキ属、カリブラコア(Calibrachoa hybrid Cultivar)等のカリブラコア属等があげられる。前記イネ科は、例えば、トウモロコシ(Zea mays)等のトウモロコシ属、イネ(Oryza sativa)等のイネ属等があげられる。前記マメ科は、例えば、ダイズ(Glycine max)等のダイズ属等があげられる。前記バラ科は、例えば、バラ(Rosa)等のバラ属等があげられる。前記ナデシコ科は、例えば、カーネーション(Dianthus caryophyllus)等のナデシコ属等があげられる。前記キク科は、例えば、栽培ギク(Chrysantemum morifolium)等のキク属、ガーベラ(Gerbera cvs.)等のガーベラ(オオセンボンヤリ)属等があげられる。前記リンドウ科は、例えば、トルコキキョウ(Eustoma grandiflorum)等のユーストマ属等があげられる。前記ゴマノハグサ科は、例えば、トレニア(Torenia fournieri)トレニア属等があげられる。前記クマツヅラ科は、例えば、バーベナ(Garden verbena)等のバーベナ属等があげられる。前記サクラソウ科は、例えば、シクラメン(Cyclamen persicum)等のシクラメン属等があげられる。前記サボテン科は、例えば、アウストロキリンドロプンティア属、アストロフィツム属、エキノカクツス属、エキノセレウス属、エキノプシス属、エピフィラム属、オプンティア属、カニバサボテン属、カマエセレウス属、キリンドロプンティア属、ギムノカリキウム属、シャコバサボテン属、セレニセレウス属、テフロカクツス属、ネオブクスバウミア属、ネオライモンディア属、ノパレア属、フェロカクツス属、マミラリア属、メロカクツス属、リプサリス属、ロセオカクツス属、ロフォフォラ属等があげられる。前記ラン科は、例えば、ファレノプシス(Phalaenopsis cvs.)等のファレノプシス(コチョウラン)属、シンビジウム(Cymbidium cvs.)等のシンビジウム(シュンラン)属、デンドロビウムのノビル系(Dendrobium nobile hybrids)、デンドロビウムのデンファレ系(D. phalaenopsis hybrids)等のデンドロビウム(セッコク)属、オンシジウム(Oncidium cvs.)等のオンシジウム属、カトレア(Cattleya cvs.)等のカトレア属等があげられる。前記微生物は、例えば、真核生物、原核生物等があげられる。前記原核生物は、例えば、大腸菌(Escherichia coli)等のエッシェリヒア属、シュードモナス・プチダ(Pseudomonas putida)等のシュードモナス属等の細菌があげられる。前記真核生物は、例えば、サッカロミセス・セレビシエ(Saccharomyces cerevisiae)等の酵母等があげられる。前記動物細胞は、例えば、COS細胞、CHO細胞等があげられ、前記昆虫細胞は、例えば、Sf9、Sf21等があげられる。 Examples of the host include non-human hosts such as microorganisms, plants, animals, insects or cultured cells thereof, isolated human cells or cultured cells thereof, and preferably plants. When the host is a plant, the plant may be a plant body or a part thereof, for example. Examples of the plant part include organs, tissues, cells, and vegetative propagation bodies. Examples of the organ include petals, corolla, flowers, leaves, seeds, fruits, stems, roots and the like. The tissue is, for example, a part of the organ. Examples of the cells include cells collected from the plant or tissue thereof, cultured cells of the cells, protoplasts, and callus. The origin of the plant is not particularly limited, and for example, Brassicaceae, Eggplant, Gramineae, Legumes, Rosaceae, Pteridomyceae, Asteraceae, Gentianaceae, Ganodermaceae, Oenaceae, Primula, Cactiaceae, Orchidaceae Department and so on. Examples of the Brassicaceae include the Arabidopsis genus such as Arabidopsis thaliana . The family Solanaceae, for example, tobacco (Nicotiana tabacum) Nicotiana such as petunia (Petunia × hybrida) petunias genus such as (Petunia), Nierembergia (Nierembergia hippoamanica) Amamodoki genus such as, Calibrachoa (Calibrachoa hybrid Cultivar) such Examples include the genus Calibrachoa. Examples of the Gramineae include a genus of maize such as corn ( Zea mays ) and a genus of rice such as rice ( Oryza sativa ). Examples of the legumes include soybean genus such as soybean ( Glycine max ). The rose family, for example, the genus Rosa such as roses (Rosa), and the like. Examples of the Nadesico family include Nadesico genus such as carnation ( Dianthus caryophyllus ). The Compositae family, for example, chrysanthemum, such as cultivation chrysanthemum (Chrysantemum morifolium), Gerbera (Gerbera cvs.) Gerbera (Oosenbon'yari) genus, etc., and the like. The Gentianaceae includes, for example, Eustoma genus such as Eustoma grandiflorum . Examples of the genus Pleurotus include Torenia ( Torenia fournieri ) Torenia. Examples of the family Oleaceae include Verbena genus such as Verbena ( Garden verbena ). The Primulaceae, for example, Cyclamen spp such as cyclamen (Cyclamen persicum) and the like. The cactus family includes, for example, Austrokilondropuntia, Astrophytum, Echinocactus, Echinocereus, Echinopsis, Epiphylam, Opuntia, Crab Cactus, Kamaecereus, Kirindropuntia, Gymnocalycium Cactus cactus genus, Serenicerus genus, Teflocactus genus, Neobox baumia genus, Neoraimondia genus, Nopalea genus, Ferrocactus genus, Mamiglia genus, Melocatus genus, Lipsalis genus, Roseocactus genus, Lofophora genus and the like. The Orchidaceae, for example, Phalaenopsis (Phalaenopsis cvs.) Such as Phalaenopsis (Phalaenopsis) genus Cymbidium (Cymbidium cvs.) Or the like Cymbidium (Chunlan) genus, Nobile system Dendrobium (Dendrobium nobile hybrids), Denfare system Dendrobium ( D. phalaenopsis hybrids ), Oncidium genus such as Oncidium cvs. , Cattleya genus such as Cattleya cvs . Examples of the microorganism include eukaryotes and prokaryotes. The prokaryotes, for example, E. coli (Escherichia coli) Escherichia genus such as Pseudomonas putida (Pseudomonas putida) Pseudomonas such as bacteria and the like. Examples of the eukaryote include yeasts such as Saccharomyces cerevisiae . Examples of the animal cells include COS cells and CHO cells, and examples of the insect cells include Sf9 and Sf21.
 前記ポリヌクレオチドを前記宿主に導入する方法、すわなち、前記宿主の形質転換の方法は、特に制限されず、例えば、前記発現ベクターを用いて導入する方法でもよいし、前記発現ベクターを用いずに導入する公知の方法でもよい。後者の場合、前記導入方法は、例えば、前記宿主の種類に応じて、適宜設定できる。前記導入方法は、例えば、ヒートショック法、酢酸リチウム法、パーティクルガン等の遺伝子銃による導入法、リン酸カルシウム法、ポリエチレングリコール法、リポソームを用いるリポフェクション法、エレクトロポレーション法、超音波核酸導入法、DEAE-デキストラン法、微小ガラス管等を用いた直接注入法、ハイドロダイナミック法、カチオニックリポソーム法、導入補助剤を用いる方法、アグロバクテリウムを介する方法等があげられる。前記リポソームは、例えば、リポフェクタミンおよびカチオニックリポソーム等があげられ、前記導入補助剤は、例えば、アテロコラーゲン、ナノ粒子およびポリマー等があげられる。前記宿主が植物の場合、前記導入方法は、アグロバクテリウムを介する方法が好ましい。前記本発明の新規遺伝子であるポリヌクレオチドは、例えば、前記本発明の発現ベクターにより前記宿主に導入してもよい。 A method for introducing the polynucleotide into the host, that is, a method for transformation of the host is not particularly limited, and for example, a method using the expression vector may be used, or the expression vector is not used. It may be a known method introduced into. In the latter case, the introduction method can be appropriately set depending on, for example, the type of the host. Examples of the introduction method include heat shock method, lithium acetate method, introduction method using gene gun such as particle gun, calcium phosphate method, polyethylene glycol method, lipofection method using liposome, electroporation method, ultrasonic nucleic acid introduction method, DEAE -A dextran method, a direct injection method using a micro glass tube, a hydrodynamic method, a cationic liposome method, a method using an introduction aid, a method using Agrobacterium, and the like. Examples of the liposome include lipofectamine and cationic liposome, and examples of the introduction aid include atelocollagen, nanoparticles, and polymers. When the host is a plant, the introduction method is preferably an Agrobacterium-mediated method. The polynucleotide which is the novel gene of the present invention may be introduced into the host by the expression vector of the present invention, for example.
 前記宿主の培養の方法は、特に制限されず、前記宿主の種類に応じて適宜設定できる。前記宿主の培養に使用する培地は、特に制限されず、前記宿主の種類に応じて適宜決定できる。 The method for culturing the host is not particularly limited, and can be appropriately set according to the type of the host. The medium used for culturing the host is not particularly limited, and can be appropriately determined according to the type of the host.
 前記宿主の培養に使用する培地の形態は、特に制限されず、例えば、固体培地、液体培地、寒天培地等、従来公知の培地を適宜使用できる。前記培地に含まれる成分は、特に制限されない。前記培地は、例えば、市販の培地を含んでもよい。前記宿主が植物である場合、前記植物の市販培地は、特に制限されず、例えば、Murashige-Skoog(MS)培地等があげられる。前記宿主が植物細胞である場合、前記植物細胞の市販培地は、特に制限されず、例えば、ハイポネックス培地、MS培地、Gamborg B5(B5)培地、White培地等があげられる。前記宿主が微生物である場合、前記微生物の市販培地は、特に制限されず、例えば、LB培地、スーパーブロス培地、M9培地等があげられる。前記培地は、例えば、1種類を単独で使用してもよいし、2種類以上を併用してもよい。前記培地のpHは、特に制限されず、例えば、pH6~8の範囲、pH6.5~7.5の範囲である。 The form of the medium used for culturing the host is not particularly limited, and a conventionally known medium such as a solid medium, a liquid medium, or an agar medium can be used as appropriate. The components contained in the medium are not particularly limited. The medium may include a commercially available medium, for example. When the host is a plant, the commercial medium of the plant is not particularly limited, and examples thereof include Murashige-Skoog (MS) medium. When the host is a plant cell, the commercially available medium for the plant cell is not particularly limited, and examples thereof include hyponex medium, MS medium, Gamborg B5 (B5) medium, White medium and the like. When the host is a microorganism, the commercially available medium for the microorganism is not particularly limited, and examples thereof include LB medium, super broth medium, M9 medium and the like. For example, one type of the medium may be used alone, or two or more types may be used in combination. The pH of the medium is not particularly limited, and is, for example, in the range of pH 6 to 8, or in the range of pH 6.5 to 7.5.
 前記宿主の培養方法は、特に制限されず、例えば、前記宿主の種類に応じて、適宜決定できる。前記宿主が植物の場合、前記培養方法は、例えば、前記植物を土壌栽培、水性栽培する方法等があげられる。前記植物が植物細胞の場合、前記培養方法は、例えば、カルス培養、根の培養、胚珠培養、胚培養等があげられる。 The method for culturing the host is not particularly limited, and can be appropriately determined according to, for example, the type of the host. In the case where the host is a plant, examples of the culture method include a method of cultivating the plant in soil and water. When the plant is a plant cell, examples of the culture method include callus culture, root culture, ovule culture, embryo culture, and the like.
 前記宿主の培養時の培養温度は、特に制限されず、例えば、前記宿主の種類に応じて、適宜決定できる。前記宿主が植物の場合、前記培養温度は、例えば、植物の生育可能温度、生育最適温度等があげられる。具体的には、前記培養温度は、例えば、15~40℃の範囲、30~37℃の範囲等で行うことができる。前記宿主が植物細胞の場合、前記培養温度は、例えば、植物細胞の生育可能温度、生育最適温度等があげられる。具体的には、前記培養温度は、例えば、15~40℃の範囲、30~37℃の範囲等で行うことができる。 The culture temperature at the time of culturing the host is not particularly limited and can be appropriately determined according to, for example, the type of the host. In the case where the host is a plant, examples of the culture temperature include a plant-growing temperature and an optimum growth temperature. Specifically, the culture temperature can be, for example, in the range of 15 to 40 ° C., in the range of 30 to 37 ° C. In the case where the host is a plant cell, examples of the culture temperature include a plant cell growth temperature and a growth optimum temperature. Specifically, the culture temperature can be, for example, in the range of 15 to 40 ° C., in the range of 30 to 37 ° C.
 前記宿主は、例えば、好気的条件下で培養してもよく、嫌気的条件下で培養してもよい。前記好気的条件または嫌気的条件は、特に制限されず、従来公知の方法を用いて設定できる。 The host may be cultured under an aerobic condition or an anaerobic condition, for example. The aerobic condition or the anaerobic condition is not particularly limited, and can be set using a conventionally known method.
<形質転換体>
 本発明の形質転換体は、前述のように、前記本発明の新規遺伝子を含むことを特徴とする。本発明の形質転換体は、前記本発明の新規遺伝子を含むことが特徴であり、その他の構成および条件は、特に制限されない。本発明の形質転換体は、前記本発明の新規遺伝子を含むため、例えば、乾燥耐性を有する。本発明の形質転換体は、例えば、前記本発明の新規タンパク質等の説明を援用できる。
<Transformant>
As described above, the transformant of the present invention includes the novel gene of the present invention. The transformant of the present invention is characterized by including the novel gene of the present invention, and other configurations and conditions are not particularly limited. Since the transformant of the present invention contains the novel gene of the present invention, it has, for example, drought tolerance. For the transformant of the present invention, for example, the description of the novel protein of the present invention can be used.
 本発明において、前記形質転換体は、特に制限されず、動物、植物等があげられるが、植物が好ましい。前記形質転換体が動物である場合、前記形質転換体としては、例えば、ヒト大腸がん細胞等のがん細胞があげられる。前記形質転換体が植物である場合、前記植物および植物の由来は、特に制限されず、例えば、前述の説明を援用できる。具体的に、前記植物は、例えば、植物体またはその部分であってもよい。前記植物体の部分は、例えば、器官、組織、細胞または栄養繁殖体等があげられる。前記器官は、例えば、花弁、花冠、花、葉、種子、果実、茎、根等があげられる。前記組織は、例えば、前記器官の部分である。前記細胞は、例えば、前記植物体またはその組織から採取した細胞、前記細胞の培養細胞、プロトプラスト、カルス等があげられる。 In the present invention, the transformant is not particularly limited, and examples thereof include animals and plants, but plants are preferred. When the transformant is an animal, examples of the transformant include cancer cells such as human colon cancer cells. When the transformant is a plant, the origin of the plant and the plant is not particularly limited, and for example, the above description can be used. Specifically, the plant may be a plant body or a part thereof, for example. Examples of the plant part include organs, tissues, cells, and vegetative propagation bodies. Examples of the organ include petals, corolla, flowers, leaves, seeds, fruits, stems, roots and the like. The tissue is, for example, a part of the organ. Examples of the cells include cells collected from the plant or tissue thereof, cultured cells of the cells, protoplasts, and callus.
 本発明において、前記形質転換体が植物の場合、本発明の形質転換体は、例えば、さらに繁殖させることができる。この際、本発明の形質転換体は、前記繁殖材料として使用できる。前記繁殖材料は、特に制限されず、例えば、前記形質転換体の全体でもよいし、部分でもよい。前記形質転換体が、前記植物体またはその部分の場合、前記繁殖材料は、例えば、種子、果実、シュート、塊茎等の茎、塊根等の根、株、プロトプラスト、カルス等があげられる。 In the present invention, when the transformant is a plant, the transformant of the present invention can be further propagated, for example. At this time, the transformant of the present invention can be used as the propagation material. The propagation material is not particularly limited, and may be the whole or a part of the transformant, for example. When the transformant is the plant body or a part thereof, examples of the propagation material include seeds, fruits, shoots, stems such as tubers, roots such as tuberous roots, strains, protoplasts, and callus.
 本発明の形質転換体の繁殖方法は、特に制限されず、公知の方法が採用できる。前記繁殖方法は、例えば、有性生殖および無性生殖のいずれでもよく、好ましくは無性生殖である。前記無性生殖による繁殖は、例えば、栄養繁殖(vegetative propagation)があげられ、栄養生殖(vegetative reproduction)ともいう。前記栄養繁殖の方法は、特に制限されず、前記植物体またはその部分の場合、例えば、挿し芽、挿し木による繁殖、器官からの植物個体への細分化、カルスによる増殖等があげられる。前記器官は、例えば、前述したような葉、茎、根等が利用できる。 The propagation method of the transformant of the present invention is not particularly limited, and a known method can be adopted. The breeding method may be, for example, sexual reproduction or asexual reproduction, preferably asexual reproduction. The reproduction by asexual reproduction includes, for example, vegetative propagation and is also called vegetative reproduction. The method of vegetative propagation is not particularly limited, and in the case of the plant body or a part thereof, for example, bud propagation, propagation by cuttings, subdividing from an organ to a plant individual, growth by callus, and the like can be mentioned. As the organ, for example, the leaves, stems, roots and the like as described above can be used.
 前記形質転換体を栄養繁殖することにより得られる繁殖体を、以下、本発明の栄養繁殖体という。本発明の栄養繁殖体は、前記本発明の形質転換体と同一の性質を有することが好ましい。本発明の栄養繁殖体は、前記形質転換体と同様に、特に制限されず、例えば、植物体またはその部分があげられる。 Hereinafter, a propagation obtained by vegetative propagation of the transformant is referred to as a vegetative propagation of the present invention. The vegetative propagation material of the present invention preferably has the same properties as the transformant of the present invention. The vegetative propagation material of the present invention is not particularly limited as in the case of the transformant, and examples thereof include a plant or a part thereof.
 また、前記形質転換体を有性生殖した場合、例えば、種子、これから生育した生育体等の子孫が得られる。本発明の子孫は、前記本発明の形質転換体と同一の性質を得ることが好ましい。本発明の子孫は、例えば、前記形質転換体と同様に、例えば、植物体またはその部分のいずれでもよい。 In addition, when the transformant is sexually reproduced, for example, seeds, progeny such as growths grown from the seeds can be obtained. It is preferable that the progeny of the present invention obtains the same properties as the transformant of the present invention. The progeny of the present invention may be, for example, a plant or a part thereof, for example, like the transformant.
 本発明の形質転換体は、例えば、さらに加工してもよい。加工する前記形質転換体の種類は、特に制限されず、例えば、花、葉、枝等があげられる。前記形質転換体の加工品は、特に制限されず、例えば、花、葉、枝等を乾燥させたポプリ、押し花、ドライフラワー、プリザーブドフラワー、樹脂密封品等があげられる。また、本発明の加工品は、例えば、前記形質転換体の栄養繁殖体、器官、組織または細胞の加工品でもよい。 The transformant of the present invention may be further processed, for example. The kind of the transformant to be processed is not particularly limited, and examples thereof include flowers, leaves, branches and the like. The processed product of the transformant is not particularly limited, and examples thereof include potpourri, dried flowers, dried flowers, preserved flowers, and resin-sealed products obtained by drying flowers, leaves, branches and the like. The processed product of the present invention may be, for example, a processed product of a vegetative propagation body, organ, tissue or cell of the transformant.
<形質転換体の製造方法>
 本発明の形質転換体の製造方法は、前述のように、宿主に、本発明の新規遺伝子を導入する導入工程を含むことを特徴とする。本発明の形質転換体の製造方法は、宿主に、本発明の新規遺伝子を導入する導入工程を含むことを特徴とし、その他の工程および条件は、特に制限されない。本発明の形質転換体の製造方法によれば、例えば、前記本発明の形質転換体を容易に製造できる。
<Method for producing transformant>
As described above, the method for producing a transformant of the present invention includes an introduction step of introducing the novel gene of the present invention into a host. The method for producing a transformant of the present invention is characterized by including an introduction step for introducing the novel gene of the present invention into a host, and other steps and conditions are not particularly limited. According to the method for producing a transformant of the present invention, for example, the transformant of the present invention can be easily produced.
 本発明の形質転換体の製造方法は、さらに、前記宿主に、前記新規遺伝子を発現させる発現工程を含んでいてもよい。 The method for producing a transformant of the present invention may further include an expression step for expressing the novel gene in the host.
 前記導入工程において、本発明の新規遺伝子を前記宿主に導入する方法は、特に制限されず、例えば、前記本発明の新規タンパク質の製造方法における前記ポリヌクレオチドを前記宿主に導入する方法の説明を援用できる。本発明の製造方法において、前記宿主は、植物が好ましい。 In the introduction step, the method for introducing the novel gene of the present invention into the host is not particularly limited. For example, the description of the method for introducing the polynucleotide into the host in the method for producing the novel protein of the present invention is used. it can. In the production method of the present invention, the host is preferably a plant.
 前記発現工程は、例えば、宿主内で、本発明の新規遺伝子から本発明の新規タンパク質を発現させる工程である。前記発現工程において、前記宿主は、例えば、本発明の新規遺伝子または前記発現ベクターが導入された形質転換体であることが好ましく、前記形質転換体の培養により、前記宿主において本発明の新規タンパク質を発現させることが好ましい。 The expression step is, for example, a step of expressing the novel protein of the present invention from the novel gene of the present invention in a host. In the expression step, the host is preferably, for example, a transformant introduced with the novel gene of the present invention or the expression vector, and the novel protein of the present invention is expressed in the host by culturing the transformant. It is preferable to express.
 前記宿主が植物の場合、本発明の形質転換体の製造方法は、さらに、前記導入工程により得られた形質転換体を繁殖する繁殖工程を含んでもよい。前記繁殖工程における繁殖方法は、例えば、前述の説明を援用できる。また、本発明の形質転換体の製造方法は、繁殖した形質転換体から採種する採種工程を含んでもよく、さらに、前記採種工程で得られた種子から生育体を生育する生育工程を含んでもよい。 When the host is a plant, the method for producing a transformant of the present invention may further include a breeding step for breeding the transformant obtained by the introducing step. As the breeding method in the breeding process, for example, the above description can be used. In addition, the method for producing a transformant of the present invention may include a seeding step for seeding from the propagated transformant, and may further include a growth step for growing a growth body from the seed obtained in the seeding step. .
<新規蛍光タンパク質のスクリーニング方法>
 本発明の新規蛍光タンパク質のスクリーニング方法(以下、「本発明のスクリーニング方法」ともいう。)は、前述のように、前記本発明の新規タンパク質に変異を導入した候補タンパク質から、配列番号1のアミノ酸配列における170番目のアミノ酸がN以外のアミノ酸であり、且つ乾燥耐性を有するタンパク質を選抜する選抜工程を含むことを特徴とし、その他の工程および条件は、特に制限されない。本発明のスクリーニング方法によれば、例えば、蛍光活性を有するタンパク質を容易にスクリーニングできる。本発明のスクリーニング方法は、例えば、前記本発明の新規タンパク質、新規遺伝子、発現ベクター、および製造方法等の説明を援用できる。
<Screening method for novel fluorescent protein>
As described above, the novel fluorescent protein screening method of the present invention (hereinafter, also referred to as “screening method of the present invention”) is the amino acid of SEQ ID NO: 1 from the candidate protein in which mutation is introduced into the novel protein of the present invention. It includes a selection step in which the 170th amino acid in the sequence is an amino acid other than N and a protein having drought resistance is included, and the other steps and conditions are not particularly limited. According to the screening method of the present invention, for example, a protein having fluorescence activity can be easily screened. For the screening method of the present invention, for example, the description of the novel protein, novel gene, expression vector, production method and the like of the present invention can be used.
 前記候補タンパク質は、前記本発明の新規タンパク質に変異を導入したタンパク質である。前記新規タンパク質に導入する変異の種類は、特に制限されず、例えば、アミノ酸の欠失、置換、挿入および/または付加である。具体例として、前記候補タンパク質は、例えば、前記新規タンパク質のアミノ酸配列において、1もしくは数個のアミノ酸が欠失、置換、挿入および/または付加されたアミノ酸配列からなるタンパク質、または前記新規タンパク質のアミノ酸配列に対して、80%以上の同一性を有するアミノ酸配列からなるタンパク質があげられる。 The candidate protein is a protein obtained by introducing a mutation into the novel protein of the present invention. The type of mutation introduced into the novel protein is not particularly limited, and examples thereof include amino acid deletion, substitution, insertion and / or addition. As a specific example, the candidate protein is, for example, a protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of the novel protein, or the amino acid of the novel protein Examples of the protein include an amino acid sequence having 80% or more identity to the sequence.
 前記候補タンパク質のアミノ酸配列において、「1もしくは数個」は、例えば、1~43個、1~33個、1~22個、1~11個、1~9個、1~7個、1~5個、1~3個、1または2個である。 In the amino acid sequence of the candidate protein, “1 or several” means, for example, 1 to 43, 1 to 33, 1 to 22, 1 to 11, 1 to 9, 1 to 7, 1 to Five, one to three, one or two.
 前記候補タンパク質のアミノ酸配列において、「同一性」は、例えば、80%以上、85%以上、90%以上、95%以上、96%以上、97%以上、98%以上、99%以上である。 In the amino acid sequence of the candidate protein, “identity” is, for example, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more.
 前記候補タンパク質は、前記候補タンパク質のアミノ酸配列に基づき、公知のタンパク質の合成方法により製造してもよいし、遺伝子工学的手法により製造してもよい。後者の場合、本発明のスクリーニング方法は、例えば、前記新規タンパク質をコードする塩基配列、すなわち、本発明の新規遺伝子に変異を導入し、変異ポリヌクレオチドを作製する変異工程、前記変異ポリヌクレオチドから前記候補タンパク質を発現させる発現工程を含む。 The candidate protein may be produced by a known protein synthesis method based on the amino acid sequence of the candidate protein, or may be produced by a genetic engineering technique. In the latter case, the screening method of the present invention includes, for example, a nucleotide sequence encoding the novel protein, that is, a mutation step of introducing a mutation into the novel gene of the present invention to produce a mutant polynucleotide, An expression step of expressing the candidate protein.
 前記変異工程において、前記新規遺伝子に導入する変異は、特に制限されず、例えば、塩基の欠失、置換、挿入および/または付加である。前記新規遺伝子への変異の導入方法は、特に制限されず、例えば、公知のポリヌクレオチドへの変異導入方法により実施でき、具体例として、前記本発明の新規遺伝子のポリヌクレオチドのランダムな断片化とPCRを用いる再結合により、遺伝子を再構築する方法(いわゆる、DNAシャフリング法)等があげられる。 In the mutation step, the mutation to be introduced into the novel gene is not particularly limited, and is, for example, base deletion, substitution, insertion and / or addition. The method for introducing a mutation into the novel gene is not particularly limited, and can be carried out, for example, by a known method for introducing a mutation into a polynucleotide. Specific examples include random fragmentation of the polynucleotide of the novel gene of the present invention. Examples include a method of reconstructing a gene by recombination using PCR (so-called DNA shuffling method).
 前記発現工程において、前記変異ポリヌクレオチドを発現させる方法は、特に制限されず、例えば、前述の本発明の新規タンパク質の製造方法の説明を援用でき、無細胞タンパク質合成系を使用してもよいし、宿主を使用してもよい。前記宿主は、例えば、原核生物、特に、大腸菌(Escherichia coli)を用いることが好ましい。 In the expression step, the method for expressing the mutant polynucleotide is not particularly limited. For example, the description of the method for producing a novel protein of the present invention described above can be used, and a cell-free protein synthesis system may be used. A host may be used. The host is preferably, for example, a prokaryote, particularly Escherichia coli .
 本発明のスクリーニング方法は、例えば、前記発現工程において得られた候補タンパク質を精製する工程を含んでもよい。前記精製方法は、特に制限されず、例えば、塩析、各種カラムクロマトグラフィー等があげられる。前記各種精製工程において使用する溶媒は、特に制限されず、例えば、緩衝液が使用できる。本発明のスクリーニング方法は、例えば、前記発現工程において得られた候補タンパク質を、そのまま後述する選抜工程で使用してもよいし、部分的に精製した部分精製候補タンパク質を使用してもよいし、単一に精製した精製候補タンパク質を使用してもよい。 The screening method of the present invention may include, for example, a step of purifying the candidate protein obtained in the expression step. The purification method is not particularly limited, and examples thereof include salting out and various column chromatography. The solvent used in the various purification steps is not particularly limited, and for example, a buffer solution can be used. In the screening method of the present invention, for example, the candidate protein obtained in the expression step may be used as it is in the selection step described later, or a partially purified candidate protein that is partially purified may be used. A single purified candidate protein may be used.
 前記選抜工程は、候補タンパク質から、配列番号1のアミノ酸配列における170番目のアミノ酸に対応するアミノ酸が、N以外のアミノ酸であり、且つ乾燥耐性を有するタンパク質を選抜する工程である。 The selection step is a step of selecting, from the candidate proteins, a protein having an amino acid corresponding to the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 other than N and having drought resistance.
 前記選抜工程において、選抜された候補タンパク質の170番目のアミノ酸に対応するアミノ酸は、N以外のアミノ酸である。N以外のアミノ酸は、A、C、D、E、F、G、H、I、K、L、M、P、Q、R、S、T、V、W、またはYであり、好ましくは、DまたはEである。 In the selection step, the amino acid corresponding to the 170th amino acid of the selected candidate protein is an amino acid other than N. Amino acids other than N are A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y, preferably D or E.
 前記選抜工程において、前記選抜された候補タンパク質は、170番目のアミノ酸が、例えば、DまたはEに置換されており、且つ乾燥耐性を有することが好ましい。 In the selection step, it is preferable that the selected candidate protein has the 170th amino acid substituted with, for example, D or E, and has drying resistance.
 前記選抜工程において、前記候補タンパク質のアミノ酸配列の同定方法は、特に制限されず、例えば、公知のアミノ酸の同定方法により実施できる。前記候補タンパク質を前記変異ポリヌクレオチドから発現させる場合、前記候補タンパク質のアミノ酸配列は、例えば、前記変異ポリヌクレオチドの塩基配列のコドンを対応するアミノ酸配列に置き換えることで同定してもよい。 In the selection step, the method for identifying the amino acid sequence of the candidate protein is not particularly limited, and can be performed by, for example, a known amino acid identification method. When the candidate protein is expressed from the mutant polynucleotide, the amino acid sequence of the candidate protein may be identified, for example, by replacing the codon of the base sequence of the mutant polynucleotide with the corresponding amino acid sequence.
 前記選抜工程において、前記候補タンパク質の乾燥耐性の確認方法は、特に制限されず、公知の乾燥耐性の確認方法が使用でき、例えば、前記乾燥耐性の測定方法と同様の方法により、確認できる。 In the selection step, the method for confirming the drying resistance of the candidate protein is not particularly limited, and a known method for confirming drying resistance can be used. For example, it can be confirmed by the same method as the method for measuring the drying resistance.
 本発明のスクリーニング方法は、前記選抜工程において、前記配列番号1のアミノ酸配列に対して、80%以上の同一性を有するアミノ酸配列からなり、乾燥耐性を有するタンパク質を選抜することが好ましい。前記「同一性」は、例えば、前記選抜された候補タンパク質が、前記乾燥耐性を有する範囲であればよい。前記「同一性」は、例えば、80%以上、85%以上、90%以上、95%以上、96%以上、97%以上、98%以上、99%以上である。 In the screening method of the present invention, in the selection step, it is preferable to select a protein having an amino acid sequence having 80% or more identity to the amino acid sequence of SEQ ID NO: 1 and having drought tolerance. The “identity” may be, for example, a range in which the selected candidate protein has the drought tolerance. The “identity” is, for example, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more.
 次に、本発明の実施例について説明する。ただし、本発明は、下記実施例により制限されない。 Next, examples of the present invention will be described. However, the present invention is not limited by the following examples.
[実施例1]
 本発明のスクリーニング方法により、新規蛍光タンパク質をスクリーニングできることを確認した。
[Example 1]
It was confirmed that a novel fluorescent protein can be screened by the screening method of the present invention.
(1)発現ベクターの構築
 Error-prone PCR法を用いて、変異ポリヌクレオチドを作製し、前記変異ポリヌクレオチドをベクターに連結して、変異ポリヌクレオチド発現ベクターを構築した。具体的には、以下のようにして行った。まず、CpYGFPのポリヌクレオチド(配列番号3)を、以下のプライマーセットを用いて、PCR(Polymerase Chain Reaction)により増幅し、ランダムに変異が挿入された変異ポリヌクレオチドを得た。PCR反応液は、GeneMorph II Random Mutagenesis Kit(200550、Agilent Technologies社製)のキットを用い、説明書に従って調製した。
(1) Construction of expression vector Using the error-prone PCR method, a mutated polynucleotide was prepared, and the mutated polynucleotide was linked to a vector to construct a mutated polynucleotide expression vector. Specifically, it was performed as follows. First, a CpYGFP polynucleotide (SEQ ID NO: 3) was amplified by PCR (Polymerase Chain Reaction) using the following primer set to obtain a mutant polynucleotide into which mutations were randomly inserted. A PCR reaction solution was prepared according to the instructions using a kit of GeneMorph II Random Mutagenesis Kit (200550, manufactured by Agilent Technologies).
 プライマーセット
 プライマー配列1(配列番号8)
  5'-ATGCTTCCGGCTCGTATGTTG-3'
 プライマー配列2(配列番号9)
  5'-GTACGGCCGACTAGTAGGCC-3'
Primer set Primer sequence 1 (SEQ ID NO: 8)
5'-ATGCTTCCGGCTCGTATGTTG-3 '
Primer sequence 2 (SEQ ID NO: 9)
5'-GTACGGCCGACTAGTAGGCC-3 '
 前記変異ポリヌクレオチドを、制限酵素HindIIIおよびEcoRIを用いて切断し、前記制限酵素で切断したpEGFPベクター(clonetec社製)に連結した。前記pEGFPベクターは、EGFP部分において、CpYGFPのポリヌクレオチド(配列番号3)の5’末端にHisタグ配列を付加した配列(CpYGFPベクター挿入配列(配列番号10))が挿入されたベクターを使用した。前記ベクター挿入配列(配列番号10)の塩基配列は、以下の通りである。以下の塩基配列において、かっこで囲んだ塩基配列が、CpYGFPのポリヌクレオチドに対応する塩基配列であり、かっこで囲んだ外における下線部の塩基配列が、Hisタグ配列である。前記変異ポリヌクレオチドを挿入したベクターを、変異ポリヌクレオチド発現ベクターとした。このようにして、多数の変異ポリヌクレオチド発現ベクターを得た。 The mutant polynucleotide was cleaved with restriction enzymes HindIII and EcoRI and ligated to a pEGFP vector (manufactured by Clonetec) cleaved with the restriction enzyme. As the pEGFP vector, a vector in which a sequence (CpYGFP vector insertion sequence (SEQ ID NO: 10)) having a His tag sequence added to the 5 'end of a CpYGFP polynucleotide (SEQ ID NO: 3) was used in the EGFP portion. The base sequence of the vector insertion sequence (SEQ ID NO: 10) is as follows. In the following base sequences, the base sequence enclosed in parentheses is the base sequence corresponding to the CpYGFP polynucleotide, and the underlined base sequence outside the parentheses is the His tag sequence. The vector into which the mutant polynucleotide was inserted was used as a mutant polynucleotide expression vector. In this way, a large number of mutant polynucleotide expression vectors were obtained.
Figure JPOXMLDOC01-appb-I000008
Figure JPOXMLDOC01-appb-I000008
(2)大腸菌への導入
 大腸菌DH5α株に、前記変異ポリヌクレオチド発現ベクターを、それぞれ単独で、ヒートショック法により形質導入した。得られた形質転換体を、抗生物質(カルベニシリン)100μg/mLを含有するLB培地を用いて培養した。
(2) Introduction into Escherichia coli Each of the above-mentioned mutant polynucleotide expression vectors was introduced into E. coli DH5α strain by a heat shock method. The obtained transformant was cultured using an LB medium containing 100 μg / mL of an antibiotic (carbenicillin).
(3)蛍光活性の確認
 そして、培養した菌体を集菌し、光源として、LEDUV光源(NS375LIM、ナイトライド・セミコンダクター株式会社製)、フィルタとして、UL360(オーエムジー株式会社製)を用いて、前記菌体の蛍光活性を確認した。
(3) Confirmation of fluorescence activity Then, the cultured cells are collected, using an LED UV light source (NS375LIM, manufactured by Nitride Semiconductor Co., Ltd.) as a light source, and UL360 (manufactured by OMG Co., Ltd.) as a filter, The fluorescence activity of the cells was confirmed.
(4)大腸菌のシーケンス
 前記(3)で蛍光活性が確認できた菌体のコロニーを収集し、プラスミドを精製し、以下の条件でダイレクトシーケンスに供した。シーケンスプライマーは、前記(1)の前記プライマーセットを用いた。その結果、蛍光活性が確認できた前記菌体は、前記本発明の新規遺伝子(配列番号4)を有していることが確認できた。これらの結果から、本発明のスクリーニング方法により、本発明の新規蛍光タンパク質をスクリーニングできることがわかった。
(4) Escherichia coli sequence The colonies of the cells whose fluorescence activity was confirmed in (3) were collected, the plasmid was purified, and subjected to direct sequencing under the following conditions. The primer set of (1) was used as a sequencing primer. As a result, it was confirmed that the bacterial cells whose fluorescence activity was confirmed had the novel gene (SEQ ID NO: 4) of the present invention. From these results, it was found that the novel fluorescent protein of the present invention can be screened by the screening method of the present invention.
[ダイレクトシーケンスの条件]
シーケンサー     ABI 3130xl(Applied Biosystems社製)
シーケンス試薬    BigDye Terminator V1-1 cycle sequencing kit(Applied Biosystems社製)
[Direct sequence conditions]
Sequencer ABI 3130xl (Applied Biosystems)
Sequencing reagent BigDye Terminator V1-1 cycle sequencing kit (Applied Biosystems)
[実施例2]
 本発明の新規タンパク質が蛍光活性を有することを確認した。
[Example 2]
It was confirmed that the novel protein of the present invention has fluorescent activity.
(1)サンプル精製
 実施例1で得られた、前記本発明の新規遺伝子(配列番号4)を有する菌体のコロニーを収集し、抗生物質(カルベニシリン)100μg/mLを含有するLB培地において、37℃で18時間培養した。そして、培養した菌体を、6000rpm、4℃の条件で、10分間遠心し、集菌した。得られたペレットを、PBS溶液を用いて、1回洗浄した。前記洗浄後のペレットを、1.6mLのPBS溶液に懸濁した。つぎに、得られた懸濁液を、超音波ホモジナイザー(QSONICA、和研薬株式会社製)を用いて、Amp30%、1分間の条件で、超音波処理した。そして、前記処理後の懸濁液を、1300rpm、4℃の条件で、10分間遠心し、得られた上清を回収した。前記上清に、0.2ml(50%スラリー)のTALON(登録商標)Metal Affinity Resin(Z5502N、TAKARA社製)を加え、室温で1時間反応させた。前記反応液を、PBS溶液を用いて洗浄した後、300mMのイミダゾールを含有する0.5mlのPBS溶液を加え、タンパク質を溶出させた。そして、アミコンウルトラ-0.5(UFC5010、Merck Millipore社製)を用いて、前記反応液のバッファー交換を行い、PBS溶液に置換した。前記形質転換体から得られた精製サンプルを、YGFP N170Dタンパク質とし、以下の実験に使用した。前記各精製サンプル中のタンパク質濃度は、前記各サンプルを、10%SDS溶液で希釈した後、Pierce BCA Protein Assay Kit(♯23225、Pierce社製)を用いて発色させ、マイクロプレートリーダー(Infinite(登録商標) M1000Pro、TECAN社製)を用いて、562nmにおける吸光度を測定することにより決定した。また、同様にして、前記本発明の新規遺伝子(配列番号7)を有する菌体から、YGFP N170Eタンパク質を含む精製サンプルを調製した。
(1) Sample purification The colony of the microbial cell which has the said novel gene (sequence number 4) of the present invention obtained in Example 1 was collected, and in an LB medium containing antibiotics (carbenicillin) 100 μg / mL, 37 Culturing was carried out at ° C for 18 hours. Then, the cultured cells were collected by centrifugation for 10 minutes under the conditions of 6000 rpm and 4 ° C. The resulting pellet was washed once with PBS solution. The washed pellet was suspended in 1.6 mL of PBS solution. Next, the obtained suspension was subjected to ultrasonic treatment using an ultrasonic homogenizer (QSONICA, manufactured by Wakken Pharmaceutical Co., Ltd.) under the conditions of Amp 30% and 1 minute. And the suspension after the said process was centrifuged for 10 minutes on the conditions of 1300 rpm and 4 degreeC, and the obtained supernatant was collect | recovered. To the supernatant, 0.2 ml (50% slurry) of TALON (registered trademark) Metal Affinity Resin (Z5502N, manufactured by TAKARA) was added and reacted at room temperature for 1 hour. The reaction solution was washed with a PBS solution, and then 0.5 ml of a PBS solution containing 300 mM imidazole was added to elute the protein. Then, using Amicon Ultra-0.5 (UFC5010, manufactured by Merck Millipore), the reaction solution was subjected to buffer exchange and replaced with a PBS solution. The purified sample obtained from the transformant was designated as YGFP N170D protein and used in the following experiments. The protein concentration in each purified sample was determined by diluting each sample with a 10% SDS solution and then developing the color using a Pierce BCA Protein Assay Kit (# 23225, manufactured by Pierce), and using a microplate reader (Infinite (registered) (Trademark) M1000Pro, manufactured by TECAN) was used to determine the absorbance at 562 nm. Similarly, a purified sample containing YGFP N170E protein was prepared from the microbial cells having the novel gene (SEQ ID NO: 7) of the present invention.
(2)蛍光活性の測定
 前記YGFP N170Dタンパク質および前記YGFP N170Eタンパク質を、それぞれ、前記(1)で得られた前記タンパク質濃度に基づき、前記サンプル中のタンパク質濃度が、2μmol/Lとなるように希釈した。前記希釈後のサンプル70μLについて、前記マイクロプレートリーダーを用い、下記測定条件で蛍光強度(FI)を測定した。また、ポジティブコントロールとして、前記YGFP N170Dおよび前記YGFP N170Eに代えて、既知の蛍光タンパク質であるBK15(配列番号11)を用いた以外は同様にして、測定した。配列番号11のアミノ酸配列は、以下の通りである。以下のアミノ酸配列において、四角で囲んだアミノ酸(N)は、170番目のアミノ酸(アスパラギン)である。
(2) Measurement of fluorescence activity The YGFP N170D protein and the YGFP N170E protein are each diluted based on the protein concentration obtained in (1) so that the protein concentration in the sample is 2 μmol / L. did. With respect to 70 μL of the diluted sample, fluorescence intensity (FI) was measured under the following measurement conditions using the microplate reader. Further, as a positive control, measurement was carried out in the same manner except that BK15 (SEQ ID NO: 11), which is a known fluorescent protein, was used instead of the YGFP N170D and the YGFP N170E. The amino acid sequence of SEQ ID NO: 11 is as follows. In the following amino acid sequence, the amino acid (N) surrounded by a square is the 170th amino acid (asparagine).
Figure JPOXMLDOC01-appb-I000009
Figure JPOXMLDOC01-appb-I000009
(測定条件)
励起波長:350~650nm(バンド幅:5nm)
蛍光(検出)波長:350~650nm(バンド幅:5nm)
レーザー強度(Gain):100
(Measurement condition)
Excitation wavelength: 350-650 nm (bandwidth: 5 nm)
Fluorescence (detection) wavelength: 350 to 650 nm (bandwidth: 5 nm)
Laser intensity (Gain): 100
 YGFP N170Dについて、励起波長(Ex)が405nmであり、蛍光波長(Em)が508nmの場合の結果を、YGFP N170Eについて、励起波長(Ex)が406nmであり、蛍光波長(Em)が505nmの場合の結果を、および、ポジティブコントロール(BK15)について、励起波長(Ex)が398nmであり、蛍光波長(Em)が512nmの場合の結果を、表1に示す。表1に示すように、YGFP N170D、およびYGFP N170Eは、BK15と比較して、より高い蛍光活性を示した。この結果から、本発明の新規蛍光タンパク質が、蛍光活性を有することがわかった。 For YGFP N170D, the excitation wavelength (Ex) is 405 nm and the fluorescence wavelength (Em) is 508 nm. For YGFP N170E, the excitation wavelength (Ex) is 406 nm and the fluorescence wavelength (Em) is 505 nm. Table 1 shows the results and the results for the positive control (BK15) when the excitation wavelength (Ex) is 398 nm and the fluorescence wavelength (Em) is 512 nm. As shown in Table 1, YGFP N170D and YGFP N170E showed higher fluorescence activity than BK15. From this result, it was found that the novel fluorescent protein of the present invention has fluorescent activity.
Figure JPOXMLDOC01-appb-T000010
Figure JPOXMLDOC01-appb-T000010
[実施例3]
 本発明の新規タンパク質が乾燥耐性を有することを確認した。
[Example 3]
It was confirmed that the novel protein of the present invention has drought resistance.
 前記実施例2のYGFP N170DおよびYGFP N170Eを使用し、乾燥耐性を測定した。乾燥耐性の測定は、以下のようにして行った。 Dry resistance was measured using YGFP N170D and YGFP N170E of Example 2. The measurement of drying resistance was performed as follows.
 前記YGFP N170Dタンパク質およびYGFP N170Eタンパク質を、それぞれ、前記実施例2(1)で得られた前記タンパク質濃度に基づき、前記サンプル中のタンパク質濃度が、5、および0.5μg/mLとなるように希釈した。乾燥耐性の測定は、マイクロフィルトレーション装置(Bio-Dot(登録商標)、Biorad社製)を用いて行った。前記装置に、濾紙として、3枚のバイオドットSFフィルターペーパー(1620161、Biorad社製)、メンブレンとして、ニトロセルロースメンブレン(162-0147、Biorad社製)を配置した。前記装置のウェルに、500μLの前記希釈後の各サンプル(それぞれ、2.5、および0.25μgの前記タンパク質に相当)を分注した。そして、プロトコルに従い、吸引濾過を行い、前記サンプルに含まれるタンパク質を、前記メンブレンに吸着させた。前記吸着後の前記膜について、MINI UV LED UNIT(NITRIDE社製)を用い、紫外光条件下(395nm)において、PowerShot SX420 IS(Canon社製)で撮影した(ブロット直後)。前記撮影は、ISO感度ISO3,200、絞り値 F3.5、シャッタースピード 1/20の条件で行った。次に、前記膜を、室温で静置し、水分を蒸発させた。そして、前記乾燥開始から1日後(Day1)、および7日後(Day7)に、ブロット直後における撮影と同様の条件で、撮影を行った。また、コントロール1として、前記YGFP N170DおよびYGFP N170Eに代えて、前記BK15を使用し、コントロール2として、前記サンプルに代えて、タンパク質未添加のPBS溶液(0μg)を用いた以外は同様にして、実験を行った。 The YGFP N170D protein and YGFP N170E protein are diluted based on the protein concentration obtained in Example 2 (1) so that the protein concentration in the sample is 5 and 0.5 μg / mL, respectively. did. The measurement of drought resistance was performed using a microfiltration apparatus (Bio-Dot (registered trademark), manufactured by Biorad). Three biodot SF filter papers (1620161, manufactured by Biorad) were arranged as filter paper, and a nitrocellulose membrane (162-0147, manufactured by Biorad) was used as a membrane. 500 μL of each diluted sample (equivalent to 2.5 and 0.25 μg of the protein, respectively) was dispensed into the wells of the device. Then, according to the protocol, suction filtration was performed to adsorb the protein contained in the sample to the membrane. The film after the adsorption was photographed with PowerShot SX420 IS (manufactured by Canon) under ultraviolet light conditions (395 nm) using MINI UV LED UNIT (manufactured by NITRIDE) (immediately after blotting). The shooting was performed under the conditions of ISO sensitivity ISO 3,200, aperture value F3.5, shutter speed 1/20. Next, the film was allowed to stand at room temperature to evaporate water. Then, one day after the start of drying (Day 1) and 7 days after (Day 7), photographing was performed under the same conditions as those immediately after blotting. In addition, except that the BK15 was used instead of the YGFP N170D and YGFP N170E as the control 1, and the PBS solution (0 μg) without protein was used instead of the sample as the control 2, The experiment was conducted.
 この結果を図1に示す。図1は、ブロット直後、Day1およびDay7における、YGFP N170Dの蛍光を撮影した結果であり、各図において、左から順に、2.5、0.25および0μgの前記タンパク質を吸着させた結果を示し、上から順に、YGFP N170D、YGFP N170EおよびBK15の結果を示す。図1に示すように、ブロット直後では、2.5μgのタンパク質を吸着させたレーンにおいて、YGFP N170D、YGFP N170EおよびBK15のバンドが検出された。0.25μgのタンパク質を吸着させたレーンにおいても、YGFP N170D、YGFP N170EおよびBK15のバンドがわずかに検出された。Day1では、2.5μgのタンパク質を吸着させたレーンにおいて、YGFP N170DおよびYGFP N170Eのバンドが検出された。一方、BK15のバンドはわずかに検出された。さらに、0.25μgのタンパク質を吸着させたレーンにおいて、YGFP N170Eのバンドがわずかに検出された。Day7では、2.5μgのタンパク質を吸着させたレーンにおいて、YGFP N170DおよびYGFP N170Eのバンドが検出された。一方、BK15のバンドはわずかに検出された。さらに、0.25μgのタンパク質を吸着させたレーンにおいて、YGFP N170Eのバンドがわずかに検出された。このように、YGFP N170DおよびYGFP N170Eは、乾燥開始から1日および7日が経過しても、蛍光活性を有していた。以上から、本発明の新規蛍光タンパク質が、BK15と比較して、乾燥耐性を有することがわかった。 The result is shown in FIG. FIG. 1 shows the results of photographing the fluorescence of YGFP N170D in Day 1 and Day 7 immediately after blotting. In each figure, the results of adsorbing 2.5, 0.25 and 0 μg of the protein in order from the left are shown. From the top, the results of YGFP N170D, YGFP N170E and BK15 are shown. As shown in FIG. 1, immediately after blotting, YGFP N170D, YGFP N170E, and BK15 bands were detected in the lane where 2.5 μg of protein was adsorbed. Even in the lane where 0.25 μg of protein was adsorbed, YGFP N170D, YGFP N170E and BK15 bands were slightly detected. In Day 1, the bands of YGFP N170D and YGFP N170E were detected in the lane where 2.5 μg of protein was adsorbed. On the other hand, the BK15 band was slightly detected. Furthermore, in the lane where 0.25 μg of protein was adsorbed, a band of YGFP N170E was slightly detected. In Day 7, bands of YGFP N170D and YGFP N170E were detected in the lane where 2.5 μg of protein was adsorbed. On the other hand, the BK15 band was slightly detected. Furthermore, in the lane where 0.25 μg of protein was adsorbed, a band of YGFP N170E was slightly detected. Thus, YGFP N170D and YGFP N170E had fluorescent activity even after 1 day and 7 days had passed since the start of drying. From the above, it was found that the novel fluorescent protein of the present invention has drought resistance compared to BK15.
 以上、実施形態および実施例を参照して本発明を説明したが、本発明は、上記実施形態および実施例に限定されるものではない。本発明の構成や詳細には、本発明のスコープ内で当業者が理解しうる様々な変更をできる。 As mentioned above, although this invention was demonstrated with reference to embodiment and an Example, this invention is not limited to the said embodiment and Example. Various changes that can be understood by those skilled in the art can be made to the configuration and details of the present invention within the scope of the present invention.
 この出願は、2018年3月30日に出願された日本出願特願2018―068235を基礎とする優先権を主張し、その開示のすべてをここに取り込む。 This application claims priority based on Japanese Patent Application No. 2018-068235 filed on March 30, 2018, the entire disclosure of which is incorporated herein.
 本発明によれば、新規な蛍光タンパク質を提供できる。このため、本発明は、例えば、生命科学分野、医療分野、農芸分野等の分野において、極めて有用な技術といえる。 According to the present invention, a novel fluorescent protein can be provided. For this reason, the present invention can be said to be an extremely useful technique in fields such as the life science field, the medical field, and the agricultural field.
 上記の実施形態の一部または全部は、以下の付記のようにも記載しうるが、以下には限定されない。
(付記1)
下記(F1)または(F2)のタンパク質であることを特徴とする、新規タンパク質。
(F1) 配列番号1のアミノ酸配列において、
170番目のアミノ酸がN以外のアミノ酸であるアミノ酸配列からなるタンパク質
(F2) 前記(F1)のアミノ酸配列に対して、170番目のアミノ酸を含む同一性が80%以上のアミノ酸配列からなり、且つ、乾燥耐性を有するタンパク質
(付記2)
前記(F1)のタンパク質が、配列番号2および6の少なくとも一方のアミノ酸配列からなるタンパク質である、付記1記載の新規タンパク質。
(付記3)
下記(f1)および(f2)の少なくとも一方のポリヌクレオチドからなることを特徴とする、新規遺伝子。
(f1) 配列番号3の塩基配列において、508番目の塩基、509番目の塩基、および510番目の塩基が、N以外のアミノ酸をコードするコドンに変異しているポリヌクレオチド
(f2) 前記(f1)のポリヌクレオチドに対して、508番目の塩基、509番目の塩基、および510番目の塩基を含む同一性が80%以上の塩基配列からなり、且つ、乾燥耐性を有するタンパク質をコードするポリヌクレオチド
(付記4)
前記配列番号3の塩基配列において、
508番目の塩基、509番目の塩基、および510番目の塩基が、DおよびEの少なくとも一方をコードするコドンである、付記3記載の新規遺伝子。
(付記5)
381番目の塩基が、Aに置換された、付記3または4記載の新規遺伝子。
(付記6)
前記(f1)のポリヌクレオチドが、配列番号4および7の少なくとも一方の塩基配列からなるポリヌクレオチドである、付記3から5のいずれかに記載の新規遺伝子。
(付記7)
前記(f2)のポリヌクレオチドが、配列番号5の塩基配列からなるポリヌクレオチドである、付記3から6のいずれかに記載の新規遺伝子。
(付記8)
付記3から7のいずれかに記載の新規遺伝子を含むことを特徴とする、発現ベクター。
(付記9)
付記3から7のいずれかに記載の新規遺伝子を含むことを特徴とする、形質転換体。
(付記10)
前記形質転換体が、植物である、付記9記載の形質転換体。
(付記11)
宿主に、付記3から7のいずれかに記載の新規遺伝子を導入する導入工程を含むことを特徴とする、形質転換体の製造方法。
(付記12)
さらに、前記宿主に、前記新規遺伝子を発現させる発現工程を含む、付記11記載の形質転換体の製造方法。
(付記13)
前記宿主が、植物である、付記11または12記載の形質転換体の製造方法。
(付記14)
配列番号1のアミノ酸配列からなるタンパク質または付記1もしくは2記載の新規タンパク質に変異を導入した候補タンパク質から、配列番号1のアミノ酸配列における170番目のアミノ酸に対応するアミノ酸がN以外のアミノ酸であり、且つ乾燥耐性を有するタンパク質を選抜する選抜工程を含むことを特徴とする、新規蛍光タンパク質のスクリーニング方法。
(付記15)
前記選抜工程において、
前記配列番号1のアミノ酸配列における170番目のアミノ酸に対応するアミノ酸が、DまたはEであり、
且つ乾燥耐性を有するタンパク質を選抜する、付記14記載のスクリーニング方法。
(付記16)
配列番号3の塩基配列からなるポリヌクレオチドまたは付記3から6のいずれかに記載の新規遺伝子に変異を導入した変異ポリヌクレオチドがコードする候補タンパク質から、配列番号1のアミノ酸配列における170番目のアミノ酸がN以外のアミノ酸であり、且つ乾燥耐性を有するタンパク質を選抜する、付記14または15記載のスクリーニング方法。
A part or all of the above embodiment can be described as in the following supplementary notes, but is not limited to the following.
(Appendix 1)
A novel protein characterized by being a protein of the following (F1) or (F2).
(F1) In the amino acid sequence of SEQ ID NO: 1,
A protein comprising an amino acid sequence in which the 170th amino acid is an amino acid other than N (F2) The amino acid sequence comprising the 170th amino acid consists of an amino acid sequence of 80% or more of the amino acid sequence of (F1), and Protein with drought resistance (Appendix 2)
The novel protein according to appendix 1, wherein the protein of (F1) is a protein comprising at least one amino acid sequence of SEQ ID NOs: 2 and 6.
(Appendix 3)
A novel gene comprising at least one of the following polynucleotides (f1) and (f2):
(F1) a polynucleotide in which the 508th base, the 509th base, and the 510th base are mutated to a codon encoding an amino acid other than N in the base sequence of SEQ ID NO: 3 (f1) A polynucleotide encoding a protein having a nucleotide sequence of 80% or more identity including the 508th base, the 509th base, and the 510th base, and having a drought resistance (Notes) 4)
In the base sequence of SEQ ID NO: 3,
The novel gene according to appendix 3, wherein the 508th base, the 509th base, and the 510th base are codons encoding at least one of D and E.
(Appendix 5)
5. The novel gene according to appendix 3 or 4, wherein the 381st base is replaced with A.
(Appendix 6)
The novel gene according to any one of appendices 3 to 5, wherein the polynucleotide of (f1) is a polynucleotide comprising at least one base sequence of SEQ ID NOs: 4 and 7.
(Appendix 7)
The novel gene according to any one of appendices 3 to 6, wherein the polynucleotide (f2) is a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 5.
(Appendix 8)
An expression vector comprising the novel gene according to any one of appendices 3 to 7.
(Appendix 9)
A transformant comprising the novel gene according to any one of appendices 3 to 7.
(Appendix 10)
The transformant according to appendix 9, wherein the transformant is a plant.
(Appendix 11)
A method for producing a transformant, comprising an introduction step of introducing the novel gene according to any one of appendices 3 to 7 into a host.
(Appendix 12)
The method for producing a transformant according to appendix 11, further comprising an expression step of expressing the novel gene in the host.
(Appendix 13)
The method for producing a transformant according to appendix 11 or 12, wherein the host is a plant.
(Appendix 14)
An amino acid corresponding to the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 is an amino acid other than N, from a protein comprising the amino acid sequence of SEQ ID NO: 1 or a candidate protein in which a mutation has been introduced into the novel protein of Appendix 1 or 2; A screening method for a novel fluorescent protein, comprising a selection step of selecting a protein having drought resistance.
(Appendix 15)
In the selection process,
The amino acid corresponding to the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 is D or E;
The screening method according to appendix 14, wherein a protein having drought resistance is selected.
(Appendix 16)
From the candidate protein encoded by the polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 3 or the mutated polynucleotide obtained by introducing mutation into the novel gene according to any one of appendices 3 to 6, the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 The screening method according to appendix 14 or 15, wherein a protein that is an amino acid other than N and has drought tolerance is selected.

Claims (16)

  1. 下記(F1)または(F2)のタンパク質であることを特徴とする、新規タンパク質。
    (F1) 配列番号1のアミノ酸配列において、
    170番目のアミノ酸がN以外のアミノ酸であるアミノ酸配列からなるタンパク質
    (F2) 前記(F1)のアミノ酸配列に対して、170番目のアミノ酸を含む同一性が80%以上のアミノ酸配列からなり、且つ、乾燥耐性を有するタンパク質
    A novel protein characterized by being a protein of the following (F1) or (F2).
    (F1) In the amino acid sequence of SEQ ID NO: 1,
    A protein comprising an amino acid sequence in which the 170th amino acid is an amino acid other than N (F2) The amino acid sequence comprising the 170th amino acid consists of an amino acid sequence of 80% or more of the amino acid sequence of (F1), and Protein with drought resistance
  2. 前記(F1)のタンパク質が、配列番号2および6の少なくとも一方のアミノ酸配列からなるタンパク質である、請求項1記載の新規タンパク質。 The novel protein according to claim 1, wherein the protein of (F1) is a protein consisting of at least one amino acid sequence of SEQ ID NOs: 2 and 6.
  3. 下記(f1)および(f2)の少なくとも一方のポリヌクレオチドからなることを特徴とする、新規遺伝子。
    (f1) 配列番号3の塩基配列において、508番目の塩基、509番目の塩基、および510番目の塩基が、N以外のアミノ酸をコードするコドンに変異しているポリヌクレオチド
    (f2) 前記(f1)のポリヌクレオチドに対して、508番目の塩基、509番目の塩基、および510番目の塩基を含む同一性が80%以上の塩基配列からなり、且つ、乾燥耐性を有するタンパク質をコードするポリヌクレオチド
    A novel gene comprising at least one of the following polynucleotides (f1) and (f2):
    (F1) a polynucleotide in which the 508th base, the 509th base, and the 510th base are mutated to a codon encoding an amino acid other than N in the base sequence of SEQ ID NO: 3 (f1) A polynucleotide encoding a protein comprising a nucleotide sequence having an identity of 80% or more and containing 508th base, 509th base, and 510th base, and having drought resistance
  4. 前記配列番号3の塩基配列において、
    508番目の塩基、509番目の塩基、および510番目の塩基が、DおよびEの少なくとも一方をコードするコドンである、請求項3記載の新規遺伝子。
    In the base sequence of SEQ ID NO: 3,
    The novel gene according to claim 3, wherein the 508th base, the 509th base, and the 510th base are codons encoding at least one of D and E.
  5. 381番目の塩基が、Aに置換された、請求項3または4記載の新規遺伝子。 The novel gene according to claim 3 or 4, wherein the 381st base is replaced with A.
  6. 前記(f1)のポリヌクレオチドが、配列番号4および7の少なくとも一方の塩基配列からなるポリヌクレオチドである、請求項3から5のいずれか一項に記載の新規遺伝子。 The novel gene according to any one of claims 3 to 5, wherein the polynucleotide (f1) is a polynucleotide comprising at least one base sequence of SEQ ID NOs: 4 and 7.
  7. 前記(f2)のポリヌクレオチドが、配列番号5の塩基配列からなるポリヌクレオチドである、請求項3から6のいずれか一項に記載の新規遺伝子。 The novel gene according to any one of claims 3 to 6, wherein the polynucleotide (f2) is a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 5.
  8. 請求項3から7のいずれか一項に記載の新規遺伝子を含むことを特徴とする、発現ベクター。 An expression vector comprising the novel gene according to any one of claims 3 to 7.
  9. 請求項3から7のいずれか一項に記載の新規遺伝子を含むことを特徴とする、形質転換体。 A transformant comprising the novel gene according to any one of claims 3 to 7.
  10. 前記形質転換体が、植物である、請求項9記載の形質転換体。 The transformant according to claim 9, wherein the transformant is a plant.
  11. 宿主に、付記3から7のいずれかに記載の新規遺伝子を導入する導入工程を含むことを特徴とする、形質転換体の製造方法。 A method for producing a transformant, comprising an introduction step of introducing the novel gene according to any one of appendices 3 to 7 into a host.
  12. さらに、前記宿主に、前記新規遺伝子を発現させる発現工程を含む、請求項11記載の形質転換体の製造方法。 The method for producing a transformant according to claim 11, further comprising an expression step of expressing the novel gene in the host.
  13. 前記宿主が、植物である、請求項11または12記載の形質転換体の製造方法。 The method for producing a transformant according to claim 11 or 12, wherein the host is a plant.
  14. 配列番号1のアミノ酸配列からなるタンパク質または請求項1もしくは2記載の新規タンパク質に変異を導入した候補タンパク質から、配列番号1のアミノ酸配列における170番目のアミノ酸に対応するアミノ酸がN以外のアミノ酸であり、且つ乾燥耐性を有するタンパク質を選抜する選抜工程を含むことを特徴とする、新規蛍光タンパク質のスクリーニング方法。 The amino acid corresponding to the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 is an amino acid other than N from a protein comprising the amino acid sequence of SEQ ID NO: 1 or a candidate protein in which a mutation is introduced into the novel protein of claim 1 or 2 A screening method for a novel fluorescent protein, comprising a selection step of selecting a protein having drought resistance.
  15. 前記選抜工程において、
    前記配列番号1のアミノ酸配列における170番目のアミノ酸に対応するアミノ酸が、DまたはEであり、
    且つ乾燥耐性を有するタンパク質を選抜する、請求項14記載のスクリーニング方法。
    In the selection process,
    The amino acid corresponding to the 170th amino acid in the amino acid sequence of SEQ ID NO: 1 is D or E;
    The screening method according to claim 14, wherein a protein having drought resistance is selected.
  16. 配列番号3の塩基配列からなるポリヌクレオチドまたは請求項3から6のいずれか一項に記載の新規遺伝子に変異を導入した変異ポリヌクレオチドがコードする候補タンパク質から、配列番号1のアミノ酸配列における170番目のアミノ酸がN以外のアミノ酸であり、且つ乾燥耐性を有するタンパク質を選抜する、請求項14または15記載のスクリーニング方法。
     
    170th position in the amino acid sequence of SEQ ID NO: 1 from a candidate protein encoded by a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 3 or a mutant polynucleotide having a mutation introduced into the novel gene according to any one of claims 3 to 6 The screening method according to claim 14 or 15, wherein the amino acid is an amino acid other than N and a protein having drought tolerance is selected.
PCT/JP2018/034338 2018-03-30 2018-09-18 Novel protein, novel gene, transformant, method for producing transformant, and method for screening novel fluorescent protein WO2019187218A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020508958A JP6933409B2 (en) 2018-03-30 2018-09-18 New protein, new gene, transformant, method for producing transformant, and method for screening new fluorescent protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018068235 2018-03-30
JP2018-068235 2018-03-30

Publications (1)

Publication Number Publication Date
WO2019187218A1 true WO2019187218A1 (en) 2019-10-03

Family

ID=68061012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/034338 WO2019187218A1 (en) 2018-03-30 2018-09-18 Novel protein, novel gene, transformant, method for producing transformant, and method for screening novel fluorescent protein

Country Status (2)

Country Link
JP (1) JP6933409B2 (en)
WO (1) WO2019187218A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100565A1 (en) * 2004-03-31 2005-10-27 Nec Soft Ltd. Novel fluorescent protein and gene coding for the same
WO2016204123A1 (en) * 2015-06-19 2016-12-22 Necソリューションイノベータ株式会社 Novel protein, novel gene, expression vector, transformant, method for producing transformant, and method for screening for novel fluorescent protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100565A1 (en) * 2004-03-31 2005-10-27 Nec Soft Ltd. Novel fluorescent protein and gene coding for the same
WO2016204123A1 (en) * 2015-06-19 2016-12-22 Necソリューションイノベータ株式会社 Novel protein, novel gene, expression vector, transformant, method for producing transformant, and method for screening for novel fluorescent protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAKRABORTEE, SOHINI ET AL.: "Intrinsically disordered proteins as molecular shields", MOLECULAR BIOSYSTEMS, vol. 8, no. 1, 1 January 2012 (2012-01-01), pages 210 - 219, XP055642196 *
SASAKI, KATSUTOMO ET AL: "Development of "Gleaming Flowers"Focus on improvement of viewing method and practical application", SEIBUTSU-KOGAKU KAISHI, vol. 92, no. 10, pages 545 - 548 *

Also Published As

Publication number Publication date
JP6933409B2 (en) 2021-09-08
JPWO2019187218A1 (en) 2021-02-12

Similar Documents

Publication Publication Date Title
CN107176982B (en) Regulate and control the transcription factor and its encoding gene and application that rubber tree anthocyanidin synthesizes
JP4741994B2 (en) Application of fluorescent protein to horticultural plants
KR100896487B1 (en) OsRDCP1 gene increasing plant stress resistance and transgenic plants transformed by OsRDCP1 gene
CN109825482B (en) Herbicide-resistant gene and application thereof in plant breeding
CN101503690B (en) The method that plant seed increases and cotton fiber increases is promoted with RDL1 gene
WO2016204123A1 (en) Novel protein, novel gene, expression vector, transformant, method for producing transformant, and method for screening for novel fluorescent protein
JP6933409B2 (en) New protein, new gene, transformant, method for producing transformant, and method for screening new fluorescent protein
JP7031929B2 (en) New proteins and new genes
JPWO2006057306A1 (en) Gramineae plant with improved stress tolerance and / or productivity, and method for producing the same
JP2004000130A (en) Zearalenone detoxification enzyme gene and transformant transferred with the same
CN114277014A (en) Application of arabidopsis AT5G10290 gene in regulation and control of plant growth
WO2018100803A1 (en) Fluorescent protein complex and light-emitting method of fluorescent protein
JP7482563B1 (en) Luminescence-related genes from Shiinotomoshibitake
JP5477619B2 (en) Glycosylation enzyme isolated from Delphinium spp. And use thereof
CN114774377B (en) HPPD proteins, genes, vectors, cells, compositions, uses thereof and methods for increasing herbicide resistance in crops
JP5447806B2 (en) Methylase isolated from sweet pea
CN113227383B (en) Role of HAK gene in regulating and controlling plant traits
JP5002167B2 (en) Genes involved in stress tolerance
CN113388593B (en) Application of Os07g0503900 protein in regulation and control of weed resistance of plants
WO2005026345A1 (en) Plant dwarfing gene
JP4464879B2 (en) Genes involved in the initiation of nodule formation and their utilization
JP2004242510A (en) Plant having improved productivity and method for creating the same
CN116926114A (en) Application of heat shock protein gene LbHSP90 in changing low temperature stress resistance of cut lily
CN113388014A (en) Application of Os02g0589400 protein in regulation and control of plant allelopathy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18912950

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020508958

Country of ref document: JP

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 18912950

Country of ref document: EP

Kind code of ref document: A1